header logo image


Page 493«..1020..492493494495..500510..»

Detector Switches Market Growth By Manufacturers, Type And Application, Forecast To 2026 – 3rd Watch News

July 7th, 2020 4:50 pm

New Jersey, United States,- Market Research Intellect sheds light on the market scope, potential, and performance perspective of the Global Detector Switches Market by carrying out an extensive market analysis. Pivotal market aspects like market trends, the shift in customer preferences, fluctuating consumption, cost volatility, the product range available in the market, growth rate, drivers and constraints, financial standing, and challenges existing in the market are comprehensively evaluated to deduce their impact on the growth of the market in the coming years. The report also gives an industry-wide competitive analysis, highlighting the different market segments, individual market share of leading players, and the contemporary market scenario and the most vital elements to study while assessing the global Detector Switches market.

The research study includes the latest updates about the COVID-19 impact on the Detector Switches sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Leading Detector Switches manufacturers/companies operating at both regional and global levels:

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=272022&utm_source=3WN&utm_medium=888

The Detector Switches market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Detector Switches market.

This study analyzes the growth of Detector Switches based on the present, past and futuristic data and will render complete information about the Detector Switches industry to the market-leading industry players that will guide the direction of the Detector Switches market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.

Sales Forecast:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Detector Switches market. Additionally, it includes a share of each segment of the Detector Switches market, giving methodical information about types and applications of the market.

Reasons for Buying Detector Switches Market Report

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It renders an in-depth analysis for changing competitive dynamics.

It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Detector Switches market.

This report helps the readers understand key product segments and their future.

Have Any Query? Ask Our Expert @ https://www.marketresearchintellect.com/need-customization/?rid=272022&utm_source=3WN&utm_medium=888

In the end, the Detector Switches market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the global Detector Switches market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Solid State LiDAR sensor Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Solubility Enhancement Excipients Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Sound Barrier Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Soy Beverage Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Soy Desserts Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Go here to read the rest:
Detector Switches Market Growth By Manufacturers, Type And Application, Forecast To 2026 - 3rd Watch News

Read More...

Global Plasma Therapy Market: Industry Size, Growth, Analysis And Forecast of 2023 – 3rd Watch News

July 7th, 2020 4:50 pm

Global Plasma Therapy Industry

New Study on 2018-2023 Plasma Therapy Market Global Key Player, Demand, Growth, Opportunities and Analysis Forecast added to Wise Guy Reports Database

The market for plasma therapy across the globe is expected to propel significantly during the forecast period. The global plasma therapy market is expected to grow impressively with a CAGR of 13.1% during 2018-2023. The factors driving the plasma therapy market are rising prevalence of life threatening diseases which includes various neurological system disorders such as chronic inflammatory demyelinating polyneuropathy (CIPD), idiopathic thrombocytopenic purpura (ITP), multifocal motor neuropathy (MMN). In addition, the rise in the occurrence of contagious diseases such as hepatitis A&B, tetanus and rabies is estimated to impact the market positively during the forecast period.

Try Sample Report @ https://www.wiseguyreports.com/sample-request/3204468-global-plasma-therapy-market-research-and-forecast-2018-2023

With an impressive technological advancement over the period has added much more to the therapies for treatment of various diseases which has also led to introduction of cost effective protein fractioning technologies from plasma. This is also being seen as a major booster to the growth within the plasma therapy market during the forecast period. As per estimates by WHO about 108 million global blood donations come from the high-income countries, which is the home for 18% of the worlds population. Presence of favourable government initiates for the development of plasma derived medicine and rising awareness regarding the importance of blood donation are the key drivers for this market.

On the geographical forefront, North America is a leader held the market share in 2017 which is expected to sustain during the forecast period as well. This is mainly due to the growing number of hospitals and clinics which is increasing the demand for the plasma derived from proteins. They key driving forces expected to boost the market of plasma therapy in North America are rising awareness levels among the blood donors, presence of advanced protein fractioning procedures, and higher per capita income in the developed countries. Furthermore, APAC region is also considered to be fastest growing region mainly due to growing medical tourism, technological advancement, rising disposable income of the patients, rising healthcare practitioners awareness, and increasing government initiatives pertaining to the development of plasma protein medicines are expected to fuel the demand of plasma protein product. The report includes detailed market overview, market determinants, company profiling, sector analysis, market segmentation, geographical analysis, strategic recommendations, key company analysis, key findings, market estimations, market insights, analyst insights and predictive analysis of the market.

Key players of plasma therapy market include CSL limited, Telecris, Baxter, Grifols, Octapharma, Kedrion, and Chengdu Inst, Japan Red Cross, LFB group (France), Shanghai Blood Institute, BPL group (UK), and Sanquin.

RESEARCH METHODOLOGY

The market study of plasma therapy market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analysing various regional players, regional tax laws and policies, consumer behaviour and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.

Secondary sources include:

Financial reports of companies involved in the marketAuthentic Public DatabasesWhitepapers, research-papers and news blogsCompany websites and their product catalogue.Supplier Websites such as Alibaba, amazon for pricing analysis.The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models such as PEST analysis, Porter five analysis delivering insights into the market for better business decisions.

The Report Covers:

Comprehensive research methodology of global plasma therapy marketIn-depth analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the global plasma therapy marketInsights about market determinants which are stimulating the global plasma therapy marketDetailed and extensive market segments with regional distribution of forecasted revenuesExtensive profiles and recent developments of market players

Some points from table of content:

REPORT SUMMARY1.1. RESEARCH METHODS AND TOOLS1.2. MARKET BREAKDOWN1.2.1. BY SEGMENTS1.2.2. BY GEOGRAPHY1.2.3. VALUE CHAIN2 MARKET OVERVIEW AND INSIGHTS2.1. DEFINITION2.2. PRICING ANALYSIS2.3. ANALYST INSIGHT & CURRENT MARKET TRENDS2.3.1. KEY FINDINGS2.3.2. RECOMMENDATION2.3.3. CONCLUSION2.4. REGULATION2.4.1. REGULATIONS RELATED TO BLOOD AND BLOOD COMPONENTS2.4.2. REGULATIONS ON CLINICAL TRIALS2.4.2.1. UNITED STATES2.4.2.2. EUROPEAN UNION2.4.2.3. CHINA2.4.2.4. INDIA2.4.3. DRUG AND DEVICE REGULATIONS2.4.3.1. UNITED STATES2.4.3.2. EUROPEAN UNION2.4.3.3. CHINA2.4.3.4. INDIA2.4.3.5. JAPAN2.5. PATENT ANALYSIS

Also Read: https://www.openpr.com/news/1075237/global-plasma-therapy-market-industry-size-growth-analysis-and-forecast-of-2023.html

3 MARKET DETERMINANT3.1. MOTIVATORS3.1.1. GROWING NUMBER OF NEUROLOGICAL PATIENTS GLOBALLY3.1.2. RISING DISPOSABLE INCOME IN THE DEVELOPING COUNTRIES3.1.3. RISING CASES OF ARTHIRITIS GLOBALLY3.1.4. RISING HEALTHCARE EXPENDITURE AND R&D IN STEM CELL PRP FOR CANCER TREATMENT3.1.5. RISE IN PERSONALIZED HEALTHCARE3.2. RESTRAINTS3.2.1. HIGH COST OF PLASMA THERAPY3.2.2. LACK OF REIMBURSEMENT POLICIES3.3. OPPORTUNITIES3.3.1. RISING CASES ORTHOPAEDIC AND NEUROLOGICAL CASES3.3.2. GROWING APPLICATION IN VARIOUS FIELDS3.3.3. GROWING MEDICAL TOURISM IN EMERGING COUNTRIES3.3.4. RISING ADOPTION OF PRP IN SPORTS INJURIES3.3.5. CHALLENGES3.3.6. DEVELOPMENTS IN OTHER FIELDS OF REGENERATIVE MEDICINE3.3.7. RESTRICTED USE OF PRP FOR DIABETIC AND KIDNEY PATIENTS4 MARKET SEGMENTATION4.1. PLASMA THERAPY BY SOURCE4.1.1. AUTOLOGOUS4.1.2. ALLOGENIC4.2. PLASMA THERAPY BY APPLICATION4.2.1. ORTHOPAEDICS4.2.1.1. ARTHIRITIS4.2.1.2. BONE REPAIR AND REGENERATION4.2.1.3. CHRONIC TENDINITIS4.2.2. CARDIAC MUSCLE INJURY4.2.3. DERMATOLOGY4.2.3.1. ANDROGENIC ALOPECIA4.2.3.2. PLASTIC SURGERY4.2.4. DENTAL4.2.5. NERVE INJURY4.2.6. OTHER APPLICATIONS4.3. PLASMA THERAPY BY TYPE4.3.1. LEUKOCYTE-RICH FIBRIN4.3.2. PURE PLATELET-RICH FIBRIN4.3.3. LEUKOCYTE-RICH PRP4.3.4. PURE PRP4.4. PLASMA THERAPY BY END USERS4.4.1. HOSPITALS AND CLINICS4.4.2. RESEARCH INSTITUTES4.4.3. OTHERS5 COMPETITIVE LANDSCAPE5.1. KEY COMPANY ANALYSIS5.2. KEY STRATEGIES6 REGIONAL ANALYSIS6.1. NORTH AMERICA6.1.1. UNITED STATES6.1.2. CANADA6.2. EUROPE6.2.1. UNITED KINGDOM6.2.2. FRANCE6.2.3. GERMANY6.2.4. ITALY6.2.5. SPAIN6.2.6. REST OF THE EUROPE6.3. ASIA PACIFIC6.3.1. INDIA6.3.2. CHINA6.3.3. JAPAN6.3.4. REST OF THE ASIA PACIFIC6.4. REST OF THE WORLD7 COMPANY PROFILES7.1. BAXTER INTERNATIONAL7.2. BIOLIFE PLASMA SERVICES7.3. BIOTEST7.4. BIO PRODUCT LABORATORY LTD. (BPL)7.5. CAMBRYN BIOLOGICS LLC

Continued.

or more information or any query mail at[emailprotected]

About UsWise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:Norah Trent+1 646 845 9349 / +44 208 133 9349Follow on LinkedIn:https://www.linkedin.com/company/wise-guy-research-consultants-pvt-ltd-?trk=biz-companies-cym

View post:
Global Plasma Therapy Market: Industry Size, Growth, Analysis And Forecast of 2023 - 3rd Watch News

Read More...

Maui Detective Melvin R Johnson Arrested for OUI 4th of July – Maui Time

July 7th, 2020 4:50 pm

Mr. Melvin R. Johnson Jr. was arrested for Operating a Vehicle Under the Influence of an Intoxicant

In a recent Maui Police Department press release: Mr. Melvin R. Johnson Jr. was arrested for Operating a Vehicle Under the Influence of an Intoxicant on 07/04/2020 at 7:59 pm. Mr. Johnson is a 25-year veteran with the Maui Police Department and currently assigned to the Wailuku Criminal Investigative Division. Johnson was off-duty at the time of his arrest. Details of the incident are still under investigation. He was released after posting $1,000.00 bail. MPD will also be conducting an internal investigation into this matter.

Chief Tivoli Faaumu would like the public to know that he holds his officers accountable for their actions, on and off duty. This is an on-going investigation and every person who is arrested, is entitled to Due Process.

July 4th, 2020- Impaired Driving Enforcement Campaign RESULTS:

In continuing with the Maui Police Departments ZERO TOLERANCE approach to Impaired Driving, Officers were out in force starting Thursday July 3 and continuing through the July 4th holiday weekend.

The Maui Police Department made (10) ten arrests Operating a Vehicle Under the Influence of an Intoxicant (OVUII), and (2) two arrests for Habitually Operating a Vehicle Under the Influence of an Intoxicant. Traffic Officers also towed (10) ten vehicles related to OVUII arrests. Any vehicle that was not towed under the new County ordinance had disabling damages due to a motor vehicle crash, or there was a sober passenger able to legally drive the vehicle.

In total, the Maui Police Department conducted (15) fifteen separate checkpoints countywide screening 1331 vehicles. There were ZERO alcohol/drug impaired driving fatalities over the July 4th holiday.

As of July 5, 2020 Maui County Police have made 262 Operating a Vehicle Under the Influence of an Intoxicant (OVUII) arrests with 13 Habitually Operating a Vehicle Under the Influence of an Intoxicant for a total of 275 total year to date arrests, compared to 280 the same time last year.

In the State of Hawaii, an OVUII arrest becomes a felony on the third arrest following two prior convictions within 10 years of the instant offense. Or if a person was convicted of Habitual OVUII one or more times within 10 years prior to the instant offense.

One notable arrest during this weekends enforcement effort was the arrest of 21 year old Wailuku resident Christian Kalalau Johnson. On July 4, 2020 at 12:20AM, Mr Kalalau Johnson was stopped at an Intoxication control checkpoint located at Haleakala Highway and Hana Highway. During the screening of Mr. Kalalau Johnson, he was found to have signs of impairment. Mr. Kalalau Johnson failed the field sobriety tests and was placed under arrest. In the course of arresting Mr. Kalalau Johnson he assaulted two officers causing minor injuries to both officers. Both officers received treatment for their injuries and were able to immediately return to work.

Mr. Kalalau Johnson was subsequently arrested and charged for Operating a Vehicle Under The influence of an Intoxicant (OVUII), Resisting Arrest, and (2 counts) of Assault Against A Police Officer. Mr. Kalalau Johnson bail was set at $3,200.

comments

View original post here:
Maui Detective Melvin R Johnson Arrested for OUI 4th of July - Maui Time

Read More...

July 2020: New NIEHS Director Rick Woychik will lead with innovation – Environmental Factor Newsletter

July 7th, 2020 4:49 pm

National Institutes of Health (NIH) Director Francis Collins, M.D., Ph.D., announced selection of Richard (Rick) Woychik, Ph.D., to serve as director of NIEHS. Woychik was acting director of NIEHS from October 2019 until June 7, the official start of his new role.

Innovation has been a hallmark of Ricks scientific career and its at the center of his vision for leading NIEHS, said Collins. He will be working to support new technologies and scientific approaches throughout the field of environmental health sciences applying his proven skills in scientific excellence, creativity, and rigor to improving public health.

As NIEHS director, Woychik takes on additional responsibility as director of the National Toxicology Program (NTP), which reports directly to the U.S. Department of Health and Human Services. NTP coordinates toxicology research among NIEHS, the National Center for Toxicological Research at the U.S. Food and Drug Administration, and the National Institute for Occupational Safety and Health at the Centers for Disease Control and Prevention.

Woychik is highly respected for a long list of accomplishments in environmental epigenetics and mammalian genetics. His laboratory discovered that mutations in a gene that codes for a protein in a class called protocadherins interfered with mammalian hearing. This gene was ultimately linked to hearing loss in Cushings disease patients.

Other firsts included identifying a gene associated with polycystic kidney disease, and the first cloning of an obesity-related gene called agouti. Woychiks passion for epigenetics and environmental health sciences is rooted in his research groups discovery that the obesity trait associated with an agouti mutant mouse line was influenced during embryonic development by the epigenome.

Woychik said he will explore opportunities to embrace new technologies and implement state-of-the-art and potentially transformative scientific approaches for the NIEHS research enterprise. I am particularly interested in better integrating environmental health sciences into the All of Us Research Program and Precision Medicine programs at NIH, he wrote in an email to employees.

He added that achieving insights into the molecular mechanisms of toxicity and other physical responses to environmental exposures will be fundamental to improving risk assessments of human health impacts.

Individuals, with their unique biological make-up, respond to the environment in different ways. Our current research strategies mostly employ a one-size-fits-all approach that does not factor in this critically important variable, Woychik explained. One important element of my vision for the institute is to deal with individual genetic, epigenetic, and biological variability when establishing research strategies for studying public health and environmental toxicology.

Woychik earned his Ph.D. in molecular biology in 1984 from Case Western Reserve University in Cleveland. He moved into the field of molecular genetics during postdoctoral training in the lab of the late Philip Leder, M.D., in Harvard Medical School Department of Genetics.

In 2010, he moved to NIEHS in the role of deputy director, bringing basic science expertise in using genetics and epigenetics to study the influence of the environment. Woychik successfully led strategic planning exercises and guided implementation across a broad range of scientific disciplines. In nearly a decade of leadership at NIEHS, he built an in-depth awareness of and appreciation for the broad range of scientific activities such as toxicology, epidemiology, and more that are necessary to effectively support the environmental health sciences community.

That experience contributes to the wealth of knowledge he brings to his new role. Prior to NIEHS, Woychik served nearly 10 years as president and CEO of The Jackson Laboratory in Bar Harbor, Maine, where he established a robust record of achievements.

Citations:Alagramam KN, Murcia CL, Kwon HY, Pawlowski KS, Wright CG, Woychik RP. 2001. The mouse Ames waltzer hearing-loss mutant is caused by mutation ofPcdh15, a novel protocadherin gene. Nat Genet. 27:99102.

Bultman SJ, Michaud EJ, Woychik RP. 1992. Molecular characterization of the mouse agouti locus. Cell 71(7):11951204.

Moyer JM, Lee-Tischler MJ, Kwon HY, Schrick JJ, Avner ED, Sweeney WE, Godfrey VL, Cacheiro NL, Wilkinson JE, Woychik RP. 1994. Candidate gene associated with a mutation causing recessive polycystic kidney disease in mice. Science 264:13291333.

(Christine Bruske Flowers is director of the NIEHS Office of Communications and Public Liaison.)

Originally posted here:
July 2020: New NIEHS Director Rick Woychik will lead with innovation - Environmental Factor Newsletter

Read More...

Myriad Announces New Studies Validating the Ability of Myriad’s riskScore Test to Modify Breast Cancer Risk Prediction – BioSpace

July 7th, 2020 4:49 pm

Publications Demonstrate the Ability of the PRS Component of riskScore to Accurately Stratify Breast Cancer Risk in Women Both With and Without Pathogenic Mutations

SALT LAKE CITY, July 07, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today two recent publications validating the polygenic risk score (PRS) component of Myriads breast cancer risk stratification tool riskScore. The publications clinically validate both the ability of the PRS component of riskScore to predict breast cancer risk in asymptomatic women and modify risk estimations for patients identified with pathogenic mutations.

Historically weve considered breast cancer risk most significant for women diagnosed with pathogenic mutations in hereditary cancer genes. These studies demonstrate clearly that other genetic factors evaluated through Myriads riskScore test can dramatically alter breast cancer risk both independent of, and in combination with, gene mutations, said Nicole Lambert, president of Myriad International, Oncology and Womens Health. This information can dramatically change patient clinical management and Myriad is currently working diligently to provide access to this important information for all women.

The first study published in JCO Precision Oncology described the PRS component of riskScore in over 150,000 women. It showed that independent of other hereditary breast cancer gene mutations (e.g., BRCA1), Myriads polygenic risk score can add great value and precision to breast cancer risk estimates. The PRS was highly associated with breast cancer risk with an odds ratio of 1.47 (95% confidence interval 1.45 to 1.49) per unit standard deviation in the PRS. This translated to women in the top PRS percentile having a three-fold higher risk of breast cancer than an average risk patient.

The second study published in the Journal of the American Medical AssociationNetwork Open demonstrates the ability of Myriads polygenic risk score to improve breast cancer risk stratification in women diagnosed with pathogenic mutations in common breast cancer genes. The study evaluated over 150,000 patients and approximately 10,000 patients who were carriers of pathogenic mutations in the BRCA1, BRCA2, CHEK2, ATM and PALB2 genes who were tested at Myriad. The study demonstrated that patients with high penetrant genes such as BRCA1 and BRCA2 did not warrant changes in clinical management; however, breast cancer risks in patients with moderate penetrant genes such as CHEK2, ATM, and PALB2 could vary significantly, warranting different clinical management considerations. For example, patients with a PALB2 mutation historically have been assessed to have an approximately 50 percent lifetime risk for breast cancer. However, after incorporating the data from Myriads 86 single nucleotide polymporphism (SNP) riskScore test, patient risks varied between 26 percent to 79 percent (see Graph 1 below).

To view Graph 1: PRS Significantly Modifies Lifetime Breast Cancer Risk in Mutation Carriers please visit the following link:https://www.globenewswire.com/NewsRoom/AttachmentNg/11ac3a62-dd7e-417a-9f08-a3a3110e01db

These are some of the largest polygenic risk score studies ever published. Patient medical management can vary dramatically depending on where patients with and without pathogenic mutations fall within the risk spectrum, said Thomas P. Slavin M.D., senior vice president for Medical Affairs in Oncology at Myriad Genetic Laboratories. This information will help empower patients and clinicians to make more informed decisions based upon the most precise breast cancer risk estimates availiable.

About riskScoreriskScore is a new clinically validated personalized medicine tool that enhances Myriads myRisk Hereditary Cancer test. riskScore helps to further predict a womens lifetime risk of developing breast cancer using clinical risk factors and genetic-markers throughout the genome. The test incorporates data from more than 80 single nucleotide polymorphisms identified through 20 years of genome wide association studies in breast cancer and was prospectively validated in our laboratory to predict breast cancer risk in women of European descent. This data is then combined with a best-in-class family and personal history algorithm, the Tyrer-Cuzick model, to provide every patient with individualized breast cancer risk.

About Myriad GeneticsMyriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to providing access to this important information for all women; and the Companys strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Graph 1

PRS Significantly Modifies Lifetime Breast Cancer Risk in Mutation Carriers

See original here:
Myriad Announces New Studies Validating the Ability of Myriad's riskScore Test to Modify Breast Cancer Risk Prediction - BioSpace

Read More...

Myriad Announces Partnership with OptraHEALTH to Deliver Gene a New AI Based Information Tool for Hereditary Cancer Patients – GlobeNewswire

July 7th, 2020 4:49 pm

SALT LAKE CITY, July 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced a new collaboration with OptraHEALTH to implement a cognitive ChatBOT named Gene to provide genetic and financial assistance information to prospective patients. Gene is an AI-powered, HIPAA-compliant knowledge platform for genetic health with BOT interfaces and can answer over 500,000 health related questions pertaining to hereditary cancer. Gene interfaces with Myriads market leading online hereditary cancer quiz, which is now taken by approximately one million people per year.

We are excited to offer this innovative new tool for physicians and patients to provide best-in-class pre-test education solutions that we can supplement with live sessions when necessary, said Nicole Lambert, president of Myriad International, Oncology and Womens Health. Myriad is highly focused on making the screening and testing process as streamlined as possible for healthcare providers and the implementation of this new technology will give their patients access to unparalleled online genetic education and support tools. This is especially important in the current environment with COVID-19 where patients may not be returning to the clinic setting and pre-test education can be particularly helpful as they work remotely with the healthcare provider to determine if testing is right for them.

Gene will interactively engage individuals online, providing them with education about hereditary cancer prior to taking an online assessment to determine if they may be a candidate for genetic testing. For those who complete the preliminary assessment and meet criteria for further evaluation, Gene will automate a pre-test process that sends an educational link that displays interactive multimedia content and gives the option to start a live conversation with a patient educator, who is a certified genetic counselor. Gene can also assist in finding a healthcare provider who can help a patient make an informed, definitive decision whether testing is appropriate and then order testing if so. Myriad plans on launching the Gene chatbot for its Foresight and Prequel prenatal tests and for companion diagnostic testing in oncology later this calendar year.

About OptraHEALTH: OptraHEALTHis focused on improving outcomes for consumers and leading Life Sciences and Healthcare organizations by utilizing a next-generation Artificial Intelligence Platform. OptraHEALTHs flagship product GeneFAX is an AI-powered knowledge platform for genetic health and is available as a web plugin or mobile application.

About Myriad GeneticsMyriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, Prolaris and riskScore are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to implementation of this new technology giving patients access to unparalleled online genetic education and support tools; plans to launch the Gene chatbot for its ForeSight and Prequel prenatal tests and for hereditary cancer testing in oncology later this calendar year; details of the functionality of the Genechatbot; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Go here to read the rest:
Myriad Announces Partnership with OptraHEALTH to Deliver Gene a New AI Based Information Tool for Hereditary Cancer Patients - GlobeNewswire

Read More...

Global Molecular Biomarkers by Manufacturers, Regions, Type and Application, Forecast to 2026 – Jewish Life News

July 7th, 2020 4:49 pm

The global Molecular Biomarkers market focuses on encompassing major statistical evidence for the Molecular Biomarkers industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Molecular Biomarkers study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

This intelligence and 2026 forecasts Molecular Biomarkers industry report further exhibits a pattern of analyzing previous data sources gathered from reliable sources and sets a precedented growth trajectory for the Molecular Biomarkers market. The report also focuses on a comprehensive market revenue streams along with growth patterns, analytics focused on market trends, and the overall volume of the market.

Download PDF Sample of Molecular Biomarkers Market report @ https://hongchunresearch.com/request-a-sample/18434

The study covers the following key players:Epic SciencesAbbottGenomic HealthAtossa GeneticsBiophysicalBioTheranosticsDako (Agilent)20/20 GeneSystemsGenomeDxDiagnoCureGen-ProbeCynvenioFoundation MedicineLife TechnologiesAlereBioCept

Moreover, the Molecular Biomarkers report describes the market division based on various parameters and attributes that are based on geographical distribution, product types, applications, etc. The market segmentation clarifies further regional distribution for the Molecular Biomarkers market, business trends, potential revenue sources, and upcoming market opportunities.

Market segment by type, the Molecular Biomarkers market can be split into,GenomicsProteomicsOthers

Market segment by applications, the Molecular Biomarkers market can be split into,MedicineBiologyOther

The Molecular Biomarkers market study further highlights the segmentation of the Molecular Biomarkers industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Molecular Biomarkers report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.

In addition, the Molecular Biomarkers market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Molecular Biomarkers market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

The study encompasses a variety of analytical resources such as SWOT analysis and Porters Five Forces analysis coupled with primary and secondary research methodologies. It covers all the bases surrounding the Molecular Biomarkers industry as it explores the competitive nature of the market complete with a regional analysis.

Brief about Molecular Biomarkers Market Report with [emailprotected] https://hongchunresearch.com/report/molecular-biomarkers-market-18434

Some Point of Table of Content:

Chapter One: Molecular Biomarkers Market Overview

Chapter Two: Global Molecular Biomarkers Market Landscape by Player

Chapter Three: Players Profiles

Chapter Four: Global Molecular Biomarkers Production, Revenue (Value), Price Trend by Type

Chapter Five: Global Molecular Biomarkers Market Analysis by Application

Chapter Six: Global Molecular Biomarkers Production, Consumption, Export, Import by Region (2014-2019)

Chapter Seven: Global Molecular Biomarkers Production, Revenue (Value) by Region (2014-2019)

Chapter Eight: Molecular Biomarkers Manufacturing Analysis

Chapter Nine: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter Ten: Market Dynamics

Chapter Eleven: Global Molecular Biomarkers Market Forecast (2019-2026)

Chapter Twelve: Research Findings and Conclusion

Chapter Thirteen: Appendix continued

Check [emailprotected] https://hongchunresearch.com/check-discount/18434

List of tablesList of Tables and FiguresFigure Molecular Biomarkers Product PictureTable Global Molecular Biomarkers Production and CAGR (%) Comparison by TypeTable Profile of GenomicsTable Profile of ProteomicsTable Profile of OthersTable Molecular Biomarkers Consumption (Sales) Comparison by Application (2014-2026)Table Profile of MedicineTable Profile of BiologyTable Profile of OtherFigure Global Molecular Biomarkers Market Size (Value) and CAGR (%) (2014-2026)Figure United States Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Europe Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Germany Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure UK Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure France Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Italy Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Spain Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Russia Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Poland Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure China Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Japan Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure India Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Southeast Asia Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Malaysia Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Singapore Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Philippines Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Indonesia Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Thailand Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Vietnam Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Central and South America Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Brazil Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Mexico Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Colombia Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Middle East and Africa Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Saudi Arabia Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure United Arab Emirates Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Turkey Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Egypt Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure South Africa Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Nigeria Molecular Biomarkers Revenue and Growth Rate (2014-2026)Figure Global Molecular Biomarkers Production Status and Outlook (2014-2026)Table Global Molecular Biomarkers Production by Player (2014-2019)Table Global Molecular Biomarkers Production Share by Player (2014-2019)Figure Global Molecular Biomarkers Production Share by Player in 2018Table Molecular Biomarkers Revenue by Player (2014-2019)Table Molecular Biomarkers Revenue Market Share by Player (2014-2019)Table Molecular Biomarkers Price by Player (2014-2019)Table Molecular Biomarkers Manufacturing Base Distribution and Sales Area by PlayerTable Molecular Biomarkers Product Type by PlayerTable Mergers & Acquisitions, Expansion PlansTable Epic Sciences ProfileTable Epic Sciences Molecular Biomarkers Production, Revenue, Price and Gross Margin (2014-2019)Table Abbott ProfileTable Abbott Molecular Biomarkers Production, Revenue, Price and Gross Margin (2014-2019)Table Genomic Health ProfileTable Genomic Health Molecular Biomarkers Production, Revenue, Price and Gross Margin (2014-2019)Table Atossa Genetics ProfileTable Atossa Genetics Molecular Biomarkers Production, Revenue, Price and Gross Margin (2014-2019)Table Biophysical ProfileTable Biophysical Molecular Biomarkers Production, Revenue, Price and Gross Margin (2014-2019)Table BioTheranostics ProfileTable BioTheranostics Molecular Biomarkers Production, Revenue, Price and Gross Margin (2014-2019)Table Dako (Agilent) ProfileTable Dako (Agilent) Molecular Biomarkers Production, Revenue, Price and Gross Margin (2014-2019)Table 20/20 GeneSystems ProfileTable 20/20 GeneSystems Molecular Biomarkers Production, Revenue, Price and Gross Margin (2014-2019)Table GenomeDx ProfileTable GenomeDx Molecular Biomarkers Production, Revenue, Price and Gross Margin (2014-2019)Table DiagnoCure ProfileTable DiagnoCure Molecular Biomarkers Production, Revenue, Price and Gross Margin (2014-2019)Table Gen-Probe ProfileTable Gen-Probe Molecular Biomarkers Production, Revenue, Price and Gross Margin (2014-2019)Table Cynvenio ProfileTable Cynvenio Molecular Biomarkers Production, Revenue, Price and Gross Margin (2014-2019)Table Foundation Medicine ProfileTable Foundation Medicine Molecular Biomarkers Production, Revenue, Price and Gross Margin (2014-2019)Table Life Technologies ProfileTable Life Technologies Molecular Biomarkers Production, Revenue, Price and Gross Margin (2014-2019)Table Alere ProfileTable Alere Molecular Biomarkers Production, Revenue, Price and Gross Margin (2014-2019)Table BioCept ProfileTable BioCept Molecular Biomarkers Production, Revenue, Price and Gross Margin (2014-2019)Table Global Molecular Biomarkers Production by Type (2014-2019)Table Global Molecular Biomarkers Production Market Share by Type (2014-2019)Figure Global Molecular Biomarkers Production Market Share by Type in 2018Table Global Molecular Biomarkers Revenue by Type (2014-2019)Table Global Molecular Biomarkers Revenue Market Share by Type (2014-2019)Figure Global Molecular Biomarkers Revenue Market Share by Type in 2018Table Molecular Biomarkers Price by Type (2014-2019)Figure Global Molecular Biomarkers Production Growth Rate of Genomics (2014-2019)Figure Global Molecular Biomarkers Production Growth Rate of Proteomics (2014-2019)Figure Global Molecular Biomarkers Production Growth Rate of Others (2014-2019)Table Global Molecular Biomarkers Consumption by Application (2014-2019)Table Global Molecular Biomarkers Consumption Market Share by Application (2014-2019)Table Global Molecular Biomarkers Consumption of Medicine (2014-2019)Table Global Molecular Biomarkers Consumption of Biology (2014-2019)Table Global Molecular Biomarkers Consumption of Other (2014-2019)Table Global Molecular Biomarkers Consumption by Region (2014-2019)Table Global Molecular Biomarkers Consumption Market Share by Region (2014-2019)Table United States Molecular Biomarkers Production, Consumption, Export, Import (2014-2019)Table Europe Molecular Biomarkers Production, Consumption, Export, Import (2014-2019)Table China Molecular Biomarkers Production, Consumption, Export, Import (2014-2019)Table Japan Molecular Biomarkers Production, Consumption, Export, Import (2014-2019)Table India Molecular Biomarkers Production, Consumption, Export, Import (2014-2019)Table Southeast Asia Molecular Biomarkers Production, Consumption, Export, Import (2014-2019)Table Central and South America Molecular Biomarkers Production, Consumption, Export, Import (2014-2019)continued

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

Originally posted here:
Global Molecular Biomarkers by Manufacturers, Regions, Type and Application, Forecast to 2026 - Jewish Life News

Read More...

It Will Consume Your Life: 4 Families Take On Rare Diseases – The New York Times

July 7th, 2020 4:49 pm

I knew we had to get the kids treatment, she said.

Dr. Harald Jueppner, a pediatric nephrologist at Massachusetts General, was the researcher who first identified the mutation that caused the condition. Dr. Nizar learned that he had been studying the mutated gene, called a PTH/PTHrP receptor, for 20 years out of scientific interest. But he had never seen a patient. She told him he could now see three herself and her two sons.

She also learned that Dr. Jueppner and a colleague, Thomas Gardella, had found in lab experiments that certain peptides, or short chains of amino acids, looked promising as possible treatments for Jansens. At that point Dr. Nizar latched onto the researchers, urging them to study the peptides for Jansens. They tried one of them in animal experiments. It partially reversed some of the bone abnormalities, Dr. Jeuppner said, but, he added, remember, this mouse model of Jansens is far from being ideal.

Dr. Nizar stayed in constant contact with Dr. Jueppner and Dr. Gardella prodding them to not lose sight of the work.

Working with Neena has been an incredible experience. Dr. Jueppner said. She is a force of nature.

In 2017, Dr. Nizar set up a foundation to support research. But she was not in a good position to fund raise. We only had eight patients, and I couldnt go to GoFundMe. My family and friends are tired of giving me money, she said.

So Dr. Nizar spoke to experts at conferences hosted by the National Institutes of Health, hoping to find a way to receive research funds. With her enthusiastic prodding, Dr. Jueppner and Dr. Gardella received a grant to study and improve the peptides theyd found as a possible Jansens treatment

In 2018, Dr. Nizar asked the F.D.A. for guidance. They were surprised we didnt have a drug company, she said. I told the lady at the F.D.A. that, at this point, I am the drug company.

See the original post:
It Will Consume Your Life: 4 Families Take On Rare Diseases - The New York Times

Read More...

Study by U of T researchers reveals how bacterial toxins evolve to cause new illnesses – News@UofT

July 7th, 2020 4:49 pm

The coronavirus pandemic is a daily reminder of the far-reachingconsequences of apathogens successful invasion of human cells. And, as a new University of Toronto study on bacterial toxins shows, it does not take much for these encounters to turn deadly.

The research found that two almost identical bacterial toxins cause distinct illnesses diarrhea and fatal toxic shock syndrome by binding unrelated human receptors. It also highlights a mechanism by which pathogens have evolved distinct receptor preferences to infect different organs.

I always think of bacterial toxins as fascinating machines of death in how they find new ways to enter host tissue, saysMikko Taipale, an assistant professor of molecular genetics at the Donnelly Centre for Cellular and Biomolecular Research.

Taipaleco-led the study,published recently in the journalCell, withRoman MelnykandJean-Philippe Julien, both senior scientists at the Hospital for Sick Children and faculty members in U of Ts department of biochemistry.

Many are familiar withClostridium difficile, a gut-dwelling bacterium that can cause diarrhea. Lesser known is its close relative,Paeniclostridium sordellii, which also lives in the gut and in the female reproductive tract. Infections are rare but fatal and can occur when the bacterial toxin escapes into the bloodstream, during birth for example, and spreads into the lungs and other organs.

Both species are thought to be part of the microbiome, the bodys resident bacteria, but its not clear why they harm some people and not others.

The toxin released byC. difficileacts through Frizzled receptor proteins, which play a role in tissue regeneration. Yet, whileP. sordelliiproduces a similar toxin, it does not bind in the same way so the researchers set out to investigate.

They took an unbiased approach by systematically switching off every gene in human cells and exposing them to theP. sordelliitoxin. Cells that survived turned out to lack genes encoding cell surface proteins called semaphorins, and other experiments confirmed that two members of this class, Semaphorin6A and Semaphorin6B, are indeed the receptors for the toxin. Both receptors are present in the lungs, as expected, though their role there remains unclear.

Knowing the receptor opens the door to finding treatment. The researchers were able to halt infection in mice by co-injecting the toxin with purified semaphorin fragments, which bound and neutralized the toxin before it could reach the real receptors.

But the finding led to more surprises.

Like Frizzled, semaphorins play important roles in the body most notably in developing the nervous system, where they help guide projecting nerve fibers. Even more surprising was that it binds a receptor with no structural resemblance to Frizzled.

Here we have two toxins that are so similar to each other, but they use completely different receptors, says Taipale. We did not expect to find that.

The reason is a tiny differencebetween C. difficileandP. sordellii in particular, the surface though which both toxins contact their receptors, as revealed by cryo electron microscopy. Each toxin protein is composed of about 2,500 amino-acids and the researchers were able to pinpoint those that directly engage with the receptor. Swapping a mere 15 of these amino acids between the two toxins was sufficient to switch receptor preference. In other words, they created a P. sordellii toxin that targeted Frizzled and vice versa.

We were floored when we saw that the toxins shared a surface that each evolved to uniquely interact with distinct cells, says Julien.

It appears that, while the rest of the toxin is under strong evolutionary pressure to remain unchanged, the receptor-binding surface is free from such constraints. This allows toxins to evolve into variants that bind new receptors to invade other tissues and hosts.

Receptor switching is not unique to bacteria, however. SARS-CoV-2 and coronavirus strains that cause common cold use the same part of the now famous spike protein to bind to diverse receptors, which might explain differences in disease severity.

This is a nice example of how viruses and bacteria from completely different domains of life have found similar molecular tactics to change their receptor targets in human cells, says Taipale.

It also reminds us how much cool biology one can find in the microbial world.

The research was supported by the CIFAR Azrieli Global Scholar program, the Ontario Early Researcher Awards programand the Canada Research Chairs program.

Continue reading here:
Study by U of T researchers reveals how bacterial toxins evolve to cause new illnesses - News@UofT

Read More...

Invaio Sciences Announces New License Agreement with the University of California for Novel Technology – PRNewswire

July 7th, 2020 4:49 pm

CAMBRIDGE, Mass., July 7, 2020 /PRNewswire/ --Invaio Sciences, Inc., a Flagship portfolio company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental challenges, today announced a new, exclusive world-wide license agreement with the University of California (UC-Riverside) for a novel technology developed by Professor Hailing Jin at the University of California Riverside.

The technology is proven to control the pathogen that causes HLB/Citrus Greening - a severe plant disease carried by an insect called the Asian citrus psyllid that has dramatically and rapidly threatened the citrus industry by devastating millions of acres of citrus crops throughout the United States and abroad.

"Invaio is enthusiastic to partner with UC Riverside and advance this innovative technology to develop solutions for combating the disease HLB/Citrus Greening," said Dr. Gerardo Ramos, Chief Science Officer at Invaio Science from his Basel, Switzerland offices. "Our novel approach with a focus on natural-based solutions in connection with plant and soil health will revolutionize agricultural practices in far more beneficial ways for the health of people and the planet. This relationship with UC Riverside will allow us to continue to learn from nature and enable biologicals to perform in a sustainable and reliable way. The prospects of addressing this type of incurable devastating crop disease to help agricultural communities and improve the environmental impact of production is exciting and rewarding."

The innovation that Invaio will now license from UC Riverside harnesses naturally-occurring compounds called anti-microbial peptides produced naturally by citrus trees, that have been shown in extensive studies conducted by Dr. Jin, to kill the bacteria responsible for HLB in infected trees, and essentially "curing" infected trees. Dr. Jin, a professor of genetics, microbiology and plant pathology at UC Riverside, studies the molecular mechanisms of plant immunity and pathogen virulence, with the goal of developing effective and environmentally friendly strategies to control plant diseases and to ensure sufficient food production.

This agreement extends Invaio's proprietary capabilities in direct delivery of biologics in trees, to combat this devastating disease. Under the terms of this agreement, UC has granted Invaio an exclusive, world-wide license with the rights to sublicense to this novel technology to develop and deploy products needed by the industry.

Invaio Sciences has pioneered a novel approach to managing insect populations in a more sustainable and targeted way by controlling the nutritional function organ called the obligate microbial symbiont (OMS) to alter insect health. This new approach, coupled with the deep understanding of the inner workings of insects by Invaio's diverse team of scientists, holds the potential to dramatically reduce the need for pesticide use globallybenefiting our agriculture, health and environment.

Invaio's focus on precision delivery allows the company to take a more mindful approach to insect management. For biological delivery, Invaio leverages naturally derived systems that can be used to produce, protect, and deliver a variety of active moleculesall of which are biodegradable. The approach may also include a physical delivery system built upon proprietary 3D-printed injection tips that deliver biological active molecules into a crop vascular system, where they rapidly move throughout the plant for maximum protection.

About Invaio Sciences Invaio Sciences is a multi-platform technology company that unlocks the potential of the planet's interdependent systems to address pressing agricultural, nutritional, and environmental challenges. Founded by Flagship Pioneering in 2018, Invaio leverages discoveries from diverse fields including human therapeutics, agriculture, environmental science, and advanced manufacturing. The company's deep understanding of the physiology of insects, together with its novel approach to managing insect populations in a more sustainable and precise way, promises to refine agricultural practices and reduce the need for pesticides globally. Invaio Sciences is dedicated to developing technology that's mindful of beneficial insects, bad for pests, and safer for us all. For more information, please visit http://www.invaio.com.

Media ContactOgilvy for Flagship [emailprotected] (202) 230-1275

SOURCE Invaio Sciences

Read this article:
Invaio Sciences Announces New License Agreement with the University of California for Novel Technology - PRNewswire

Read More...

U of T and Hebrew University of Jerusalem launch research and innovation partnership – News@UofT

July 7th, 2020 4:49 pm

How did environmental conditions and climate change influence early human evolution? Can protein engineering be harnessed to block the virus that causes COVID-19? How do quantum mechanics affect biological functions, and how do our memory and learning work on a cellular level in the brain?

These are some of the big questions that will be explored by researchers at the University of Toronto and the Hebrew University of Jerusalem (HUJI) as part of a new strategic partnership that will allow faculty and students from the two institutions to combine resources to carry out high-impact research.

Each year, the University of Toronto Hebrew University of Jerusalem Research and Innovation Alliance will select projects to receive funding of $150,000 a year for up to four years, with each research group comprising faculty drawn from both universities and covering a range of disciplines. The alliance will also occasionally provide one-time seed funding to help get promising projects off the ground.

Initially launched with endowed funding of $5.9 million from the Canadian Friends of Hebrew University and the family of Roz and Ralph Halbert, the allianceaims to raise another $14 million and eventually construct an innovation pipeline between U of T and HUJI to connect the entrepreneurship ecosystems in Toronto and Jerusalem and provide student entrepreneurs with exposure to each others universities and markets.

[HUJIs] mandate with respect to research is very closely aligned to U of Ts in terms of leading the world in a variety of areas, and thats always the kind of partner were looking for, said Alex Mihailidis, U of Ts associate vice-president of international partnerships and a professor in the Faculty of Medicine's department of occupational science and occupational therapy, as well as the Institute of Biomaterials and Biomedical Engineering.

We both recognize that international collaborations strengthen the research within each university, and thats why were excited to partner with them.

He added that the timing of the partnership speaks to U of Ts commitment to forge ahead with research partnerships despite the challenges of working and collaborating amid the pandemic.

From an international partnerships perspective, its business as usual, said Mihailidis, who is also cross-appointed to the department of computer science in the Faculty of Arts & Science. Weve not shut anything down and weve not stopped collaborations. Were going full-speed ahead its looking a bit different, but we are still moving ahead both with existing and new partners.

Both researchersdeveloped an interest in the Kalahari Chazan as an archeologist analyzing early evidence of human activity and Matmon as a geologist carrying out dating techniques to study the evolution of the landscape and theyre now looking to combine their perspectives.

The next phase of work with this funding is to expand Aris geological work, particularly looking for evidence of wet environments, so we can try and understand when there was a shift to modern arid conditions, said Chazan. At the same time, Ill be working in the town of Kathu in South Africa, which is a major mining area today, and were looking at some very large sites and trying to understand what the conditions were when this place supported large groups of people.

So its a really new area of study that combines geological perspectives on how the landscape and hydrology evolved with an archeological perspective which is asking in more narrowly focused locations what the human behaviour was and what was drawing people to these sites.

Oron Shagrir, vice-president for international affairs at HUJI, said the partnership brings together the two leading universities in Israel and Canada, and that the call for research proposals resulted in several exciting submissions.

In these challenging and unprecedented times for societies and universities alike, international partnerships are an invaluable source of support and inspiration, said Shagrir, a professor of philosophy and cognitive science. They are not only an important asset and tool in advancing universities on all levels, but also serve as a valuable platform to promote and support collaborative research projects.

Chazan points to his project as an example of how the two universities can combine their respective strengths.

At U of T, were strong in terms of field archeology and geophysics, he said. Hebrew University is particularly strong in looking at the evolution of landforms over the period of the last two to five million years ... [and] that requires some very specialized labs.

Among the labs that Chazan and his students will have access to is a high-tech facility that blocks out any modern magnetic signals to precisely study fluctuations in the earths magnetic field. Having access to that is a major asset for the project and for our students, who get to learn how to operate in that kind of system, said Chazan.

Meanwhile, Sachdev Sidhu, a professor appointed to U of Ts Donnelly Centre for Cellular and Biomolecular Research, the department of molecular genetics and the Institute of Biomaterials and Biomedical Engineering, will be working with Professor Julia Shifman of HUJIs Alexander Silberman Institute of Life Science to study how the fast-growing fields of protein engineering and design can be leveraged to develop treatments for diseases, including COVID-19.

Their project will use insights gained from past outbreaks of coronaviruses to understand the functions of the proteins that power SARS-CoV-2 the virus that causes COVID-19 and to develop molecules with the potential to disarm the virus and pave the way to a potential cure.

Additionally, the U of T HUJI Research and Innovation Alliance is providing $5,000 in seed funding to two projects.

The first will see Professor Dvira Segal of U of Ts departments of chemistry and physics and Professor Roi Baer of HUJIs Fritz Haber Research Center for Molecular Dynamics and Institute of Chemistry explore the role of quantum processes in natural and engineered quantum systems.

The second aims to better understand how the brain acquires and stores information in order to help prevent and treat debilitating memory and learning disorders. The principal investigators are Associate Professors Sheena Josselyn and Paul Frankland of the department of physiology in U of Ts Faculty of Medicine, Professor Melanie Woodin of the department of cell and systems biology and HUJI scholars Adi Mizrahi, Ami Citri and Inbal Goshen.

Ronald Appleby, a U of T alumnus and campaign chair for the partnership, said the research efforts made possible by the partnership speak to the two universities shared commitment to advancing interdisciplinary teams of researchers and students working on translational research, bolstered by mutual respect and friendship.

The attention paid to research in engineering and medicine, the sciences, the social sciences, humanities, and law reflects our mutual interest in creating novel solutions for some of the most pressing current issues, Appleby said.

Read the original:
U of T and Hebrew University of Jerusalem launch research and innovation partnership - News@UofT

Read More...

Fine-tuning brain activity reverses memory problems in mice with autism mutation – Spectrum

July 7th, 2020 4:49 pm

Social circuitry: Mice with an autism-linked mutation have better social memory after treatment that calms a related neural circuit.

Georgejason / iStock

Dampening overactive brain circuits alleviates social and spatial memory problems in a mouse model of 22q11.2 deletion syndrome, according to a new study1. The findings hint at the possibility of novel treatments for some difficulties associated with the syndrome.

Deletions of DNA in a chromosomal region known as 22q11.2 often cause intellectual disability or other cognitive difficulties, as well as psychiatric conditions such as schizophrenia. About 16 percent of people with the deletion also have autism2.

The type and severity of traits vary from person to person, in part because the deletion can span roughly 20 to 50 genes. That range makes it difficult to design targeted therapies. And many people with deletions in 22q11.2 are prone to drug-related side effects, such as seizures.

Side effects with drug treatment is one of the hardest parts of dealing with mental illness, says Julia Kahn, a postdoctoral researcher at the Childrens Hospital of Philadelphia in Pennsylvania, who worked on the study. Being able to circumvent that in a very directed manner would be really life-changing for a lot of people.

The study identifies the neural circuits responsible for select behaviors in model mice and shows that manipulating those circuits could offer a new treatment strategy.

It suggests that therapies can be symptom specific, says lead investigator Douglas Coulter, professor of pediatrics and neuroscience at the University of Pennsylvania in Philadelphia.

Coulter and his colleagues manipulated circuits in two regions of the hippocampus in 22q11.2 model mice: the ventral region, which governs social memory, and the dorsal region, involved in spatial memory. They focused on the hippocampus because it is important to social cognition in both mice and people, and previous studies have shown it is unusually small in people with 22q11.2 deletions3.

Before the manipulation, mice missing 22q11.2 perform worse than controls on tests of their social and spatial memory, the study shows. The mice do not distinguish between a new mouse and one they have already met, and they have trouble recognizing when an object in their cage has been moved. Brain imaging also showed that the model mice have overactive neurons in the hippocampus.

The team used a method known as chemogenetics to dampen this overactivity. They gave the mice an injection that prompts some neurons in the hippocampus to produce designer receptors. They then injected the animals with an experimental drug that binds only to those receptors, making the neurons less excitable.

The animals behaviors changed, depending on where they received the injection. Social memory improved when the drug targeted the ventral hippocampus, and spatial memory improved when the drug affected neurons in the dorsal area. Too much inhibition in either area caused the animals memory problems to return.

Using the same technique, the researchers also gave control mice drug-sensitive receptors that either activate or quell the same circuits in the hippocampus. After both treatments, the controls showed the same social memory problems as the mice with 22q11.2 deletions. The results indicate that disrupting the circuits in either direction is enough to change behavior, even without any underlying genetic mutations. The findings were published in May in Biological Psychiatry.

Chemogenetics is a long way off from use in people, but drugs currently on the market may be able to achieve similar outcomes by nudging circuits into a more balanced state, says Peter Scambler, professor of molecular medicine at University College London in England, who was not involved in the work.

Its a proof of principle, he says.

Manipulating circuits that govern specific behaviors should be a goal of all current work at this point, says Anthony LaMantia, professor of developmental disorders and genetics at Virginia Polytechnic Institute and State University in Blacksburg, who was not involved in the work. This is much more targeted and precise. It should make everybody in the field think through how to design their experiments.

Targeting circuits in the hippocampus could help people, because findings in the hippocampus in mice typically translate well to humans, says Rebecca Piskorowski, head of the synaptic plasticity and neuronal circuits team at the Institute of Psychiatry and Neuroscience of Paris in France, who was not involved in the work.

This kind of targeting might also help at any age. The method improved memory in adult mice, suggesting similar treatments could help older people with 22q11.2 deletions and not just children.

This paper shows if you just adjust the activity in a tiny little place, you can somehow compensate for all those developmental problems, Piskorowski says. That is particularly exciting.

Read the original post:
Fine-tuning brain activity reverses memory problems in mice with autism mutation - Spectrum

Read More...

Cancer Research UK and British Heart Foundation warn Prime Minister they may have to cut 200m from research funding – Cambridge Independent

July 7th, 2020 4:49 pm

Cancer Research UK could be forced to slash 150million per year from its research funding, while the British Heart Foundation anticipates cuts its spend by half from 100million to 50million due to the loss of income caused by Covid-19.

The desperate scenario has prompted more than 60 of the UKs leading cardiovascular disease and cancer research scientists - many of them based in Cambridge - to write an open letter to the Prime Minister calling for urgent financial support for medical research charities.

Cancelled events, such as CRUKs Race for Life, and closed charity shops have decimated income for the charities, which expect a reduction in research funding for the next three to five years.

In the letter, sent today (Tuesday), the scientists warn: This will have a catastrophic and long-lasting impact on both cardiovascular and cancer research in the UK, but also on the broader R&D sector.

They call for swift action to invest in a Life Sciences-Charity Partnership Fund to protect the vital and unique contribution charity-funded biomedical research makes to the UKs R&D ecosystem and the wider economy.

Medical research charities invested 1.9 billion into UK research last year, with CRUK and the BHF alone funding more than half of all non-commercial research in the country into cancer and heart and circulatory diseases.

Professor Sir Nilesh Samani, BHFs medical director, said: Without immediate action, the UKs research base faces a devastating fall in funding that will delay progress in discovering new ways of preventing, diagnosing and treating diseases including heart attack, stroke and vascular dementia. We also risk losing a generation of promising young researchers and diminishing the UKs standing as a world leader in science. We cannot afford to let this happen during a pandemic which has underlined the critical role science and research play in the UKs healthcare and economy.

The call for a Life Sciences - Charity Partnership Fund, now backed by many of the countrys most eminent scientists, is about far more than supporting charities. It would represent a government investment in UK research, returned many times over in terms of the world leading scientific discoveries it enables, the fuel it provides to the UK economy, and the lives that will be saved through the treatments and cures that will follow.

With the Chancellor setting out a plan for the UKs economic recovery tomorrow, stabilising UK science should be at the heart of it.

The letter is signed by scientists including Professor Richard Gilbertson, Li Ka Shing chair of oncology, head of the Department of Oncology and director of the Cambridge Cancer Centre, and Prof Greg Hannon, Royal Society Wolfson research professor of cancer molecular biology and director of the CRUK Cambridge Institute at the University of Cambridge.

It adds: For every 1 the BHF invests, its researchers attract 2.14 of additional funding. CRUK is the second largest licensor in oncology in the world licences that underpin tomorrows medicines and todays investment by companies such as AstraZeneca. Charities have led to the formation of over 40 spin-out companies, which in turn have raised over a 1bn in third party investment and the creation of thousands of jobs.

The idea of a co-investment scheme that provides a level of match funding for future charity research over the next three to five years is supported by the Association of Medical Research Charities (AMRC) and 151 of its charity members.

The AMRC estimates a reduction in UK medical research investment of 310million this financial year.

BHF supports a portfolio of 446million of research at 47 UK institutions, including funding more than 1,700 researchers, hundreds of whom are in the early stages of their scientific career.

CRUK spent 422million on cancer research in 2018/19 and has 90 institutions in more than 40 UK towns and cities, including its major institute in Cambridge. It funds about 4,000 researchers in labs and hospitals across the UK, including more than 500 PhD students.

The letter warns Boris Johnson: Without your support, the UK risks a slide backwards, undermining decades of pioneering and life saving research, as well as losing a generation of new researchers and a major decline in our nations international competitiveness in life sciences that we have worked so hard to achieve.

Also among the signatories are Prof Martin Bennett, BHF professor of cardiovascular sciences at the University of Cambridge, Prof Jason Carroll, professor of molecular oncology and senior group leader at the CRUK Cambridge Institute, Prof John Danesh, of the University of Cambridge; Wellcome Sanger Institute and Health Data Research UK-Cambridge, Prof Gerard Evan, of the Department of Biochemistry at the University of Cambridge, Prof Kay-Tee Khaw of the University of Cambridge and Prof Ziad Mallat, BHF chair, professor of cardiovascular medicine at the University of Cambridge.

The letter in full

Dear Prime Minister,

We are writing to you as experts and leaders in the fields of cardiovascular and cancer research, and as British Heart Foundation (BHF) and Cancer Research UK (CRUK) funded academics carrying out research at leading UK universities, research centres and institutes. We wish to highlight the significant impact COVID-19 has had on the medical research sector and to urge you to take swift action to invest in a Life Sciences-Charity Partnership Fund to protect the vital and unique contribution charity- funded biomedical research makes to the UKs R&D ecosystem and the wider economy.

The biomedical research sector is key to the health and the wealth of the nation. We therefore welcomed the Governments commitment to make the UK the leading global hub for life sciences. We believe that the sector can be one of the key engines that will help boost the UK economy through COVID-19 recovery, leaving the EU, and beyond. Recent funding announcements, such as the university research support scheme, are positive first steps to help achieve this ambition, but we remain concerned they will not fully address the significant shortfall in charity investment in the UK science base.

The funding provided by charities plays a unique role within the wider funding mix, supporting high- risk discovery science that drives the breakthroughs in our fields (and others), as well as de-risking projects to attract commercial investment and supporting clinical trials that bring the latest innovations and life-saving treatments to patients. Charity funding invests in skills and has supported many of us earlier in our careers, allowing us to continue to build our expertise within the UK system, adding to the strength of its research base and building the UKs global reputation for research excellence.

However, both the BHF and CRUK are now seeing their incomes decimated by the COVID-19 pandemic. This will have a catastrophic and long-lasting impact on both cardiovascular and cancer research in the UK, but also on the broader R&D sector. CRUK could be forced to cut 150 million per year from its research funding, and the BHF anticipates having to cut its research spend by half this year from 100 million to around 50 million. This means a significantly lower investment in life saving high quality research, in skills and in infrastructure.

To put this challenge into context, last year, medical research charities invested 1.9 billion in research in the UK. CRUK and BHF alone funded 50% and 55% of all UK-based independent research into cancer and heart and circulatory diseases respectively something that will not be possible to maintain for the foreseeable future. Given that level of contribution, such a drastic reduction in their capacity to fund research will have a dramatic impact on the national investment in research in two key areas of unmet medical need.

Moreover, this reduction will have a knock-on impact on our partners in industry and on the inward investment into the UK life science sector. For example, for every 1 the BHF invests, its researchers attract 2.14 of additional funding. CRUK is the second largest licensor in oncology in the world licences that underpin tomorrows medicines and todays investment by companies such as AstraZeneca. Charities have led to the formation of over 40 spin out companies, which in turn have raised over a 1bn in third party investment and the creation of thousands of jobs. The Association of Medical Research Charities (AMRC) estimates a reduction in UK medical research investment of 310 million this financial year alone which will severely impact the UKs internationally recognised strength in the life sciences.

While charities are doing all they can to support existing research, we are gravely concerned for the future of biomedical research in the UK, and we fear that the latest research support package will not go far enough to plug the funding gap charities are facing. We urge you to support the proposal from CRUK and the BHF, as well as 151 other medical research charities and AMRC, to work in partnership with the sector to establish a Life Sciences-Charity Partnership Fund. This co-investment scheme is urgently needed to help protect and invest in world-class research across the UKs four nations, whose quality is assured through a stringent peer-review process, and could provide matched funding from Government for future charity research over the next 3-5 years (the period in which funding is expected to be most acutely affected).

Without your support, the UK risks a slide backwards, undermining decades of pioneering and life saving research, as well as losing a generation of new researchers and a major decline in our nations international competitiveness in life sciences that we have worked so hard to achieve. This will diminish our reputation as a world-leader in developing medical breakthroughs that save lives lost to cancer, heart and circulatory diseases and countless other conditions. We ask that you reaffirm your commitment to science and research by investing to support medical research charities in this time of need.

Signed,

Cc:

Rt Hon Rishi Sunak MP, Chancellor of the Exchequer Rt Hon Alok Sharma MP, Secretary of State for Business, Energy and Industrial Strategy Rt Hon Matt Hancock MP, Secretary of State for Health and Social Care

Read more

Revealed: 220m vision for Cambridge Cancer Research Hospital

Leading the fight against children's brain tumours: Prof Richard Gilbertson on CRUK's new centre

Cancer Research UK Cambridge Institute developing liquid biopsies for detecting brain tumours

Prof Greg Hannon on taking over at the Cancer Research UK Cambridge Institute and creating the worlds first virtual reality tumour

Prof Ziad Mallat leads Cambridge effort to win 30m to tackle leading cause of heart attacks and strokes

See the article here:
Cancer Research UK and British Heart Foundation warn Prime Minister they may have to cut 200m from research funding - Cambridge Independent

Read More...

University of Wisconsin forms new animal, dairy science department – Feedstuffs

July 7th, 2020 4:49 pm

The University of Wisconsin-Madison College of Agriculture & Life Sciences (CALS) announced July 6 the formation of the department of animal and dairy sciences, effective July 1, 2020.

The former department of animal sciences and department of dairy science, which have been operating as a single unit since early 2019, will dissolve after positions are transferred to the new department, CALS said.

After exploring the possibility of a merged unit in fall 2018, the two departments voted to begin sharing administrative roles that December. In January, they voted to have a single leadership structure as well.

Kent Weigel, a dairy cattle geneticist who has been the chair of dairy science since 2010, became the chair of both departments, and Hasan Khatib, a molecular geneticist who was serving as associate chair of animal sciences, became the associate chair of both departments. They will continue in these roles in the new department.

While the two departments have been separate units since 1962, they have similar missions and commonalities that include animal health and welfare, nutrition, reproduction, lactation, cattle genetics and genomics, animal biologics and basic science, CALS said, noting that becoming one department will lessen administrative burdens and foster unique, collaborative research. The undergraduate and graduate academic programs will remain the same, with the single department offering majors in animal science and dairy science.

The departments prepared a formal proposal that they voted on in November 2019. The proposal was approved by the CALS Academic Planning Council and University Academic Planning Council this spring.

The formation of the department of animal and dairy sciences aligns with recommendations made by the CALS organizational Redesign Committee in 2017. With these changes, the college now has 16 academic departments.

Read more from the original source:
University of Wisconsin forms new animal, dairy science department - Feedstuffs

Read More...

A Brighter Tomorrow > News > USC Dornsife – USC Dornsife College of Letters, Arts and Sciences

July 7th, 2020 4:49 pm

From environment to family, transportation to health care, from work and leisure to what well eat and how well age, USC Dornsife faculty share how they think our future world will look. [11 min read]

As the 19th century drew to a close and a new era dawned, an American civil engineer named John Elfreth Watkins consulted experts at the nations greatest institutions of science and learning for their opinions on 29 wide-ranging topics. Watkins, who was also a contributor to the Saturday Evening Post, then wrote an extraordinary magazine article based on what these university professors told him.

Published on Page 8 of the December 1900 issue of Ladies Home Journal a sister publication of the Post it was titled What May Happen in the Next Hundred Years. Watkins opened the article with the words, These prophecies will seem strange, almost impossible. In fact, many of his far-sighted predictions for the year 2000 which included the invention of digital color photography, television and mobile phones proved remarkably accurate.

For this issue of USC Dornsife Magazine, we have repeated the experiment by inviting 10 scholars drawn from USC Dornsife faculty and representing diverse disciplines to predict what the world will look like in the year 2050 and the year 2100.

A Bluer Planet

Astronauts circling the globe in 80 years may find our blue planet looking quite a bit bluer, says Naomi Levine, assistant professor of biological sciences and Earth sciences.

The middle of the Pacific or Atlantic oceans are what we call the deserts of the ocean. Theyre really low in nutrients, and things that live there are usually small. As a result, these areas look very blue because there isnt much ther except water, Levine explains. As the climate warms, we predict that these desert areas are going to expand. So, ocean waters will look bluer from space.

A Brighter Shade of Green

Our planet may also look a bit greener. Travis Williams, professor of chemistry, says that without an active plan for removing the carbon clogging our atmosphere, nature could step in.

If we dont choose a biomass thats going to utilize higher temperatures and that atmospheric carbon, nature is going to choose on our behalf, and I dont think were going to like it, he says. To avoid harmful organism explosions like algae blooms, Williams foresees a human-led reforestation of the planet, at a scale several times the size of the Amazon rainforest.

What's On the Menu?

A greening planet could also be due to changes in our agricultural systems. A move away from monoculture farming and a return to an ancient polyculture approach might be on the horizon, says Sarah Portnoy, associate professor (teaching) of Spanish. Portnoy researches indigenous food cultures of Mesoamerica and suggests that in the future we could adopt the milpa food system. Animals would be grazing on the same land where there are cover crops and squash, corn, beans and all kinds of herbs growing together, she says.

This isnt just a utopian pipe dream. Governments will have to seriously rethink agriculture if they want to reduce rising rates of chronic disease such as obesity, especially among the poor. The agriculture that is supported by the government now is skewed toward crops like soybeans and wheat. Our food system is geared to the cheapest calories, Portnoy says.

The high-calorie, processed foods produced from these monoculture, subsidized crops are less expensive than fruits and vegetables, but do little for our health. Unless we reprioritize which crops get government cash, we can expect disparities in health between economic classes to continue. By 2050, only the privileged might be able to afford strawberries or carrots.

Food supplies will alter in other ways as well, thanks to climate change. The bluer oceans will be less friendly to bigger marine organisms, which means fewer large fish to harvest.

When you change ocean temperatures, it changes what types of organisms can grow, and that cascades up the food web, says Levine. Sushi chefs in 2050 might dish up more avocados and scallops than tuna rolls. This could work for future diners, Portnoy thinks. Theres a move toward being a lot more intrepid as an eater, and toward plant-based diets, she says.

One Big, Happy Family

Starting off your day in 2050 could mean wheeling your toddler to the state-funded neighborhood day care center. Birth rates are currently plummeting across the industrialized world and governments may soon need to tackle the problem as a public health priority, says Darby Saxbe, associate professor of psychology and director of the USC Center for the Changing Family.

Well realize that, when the birth rate goes down, that affects our future workforce, she says. When were not able to replace our population, it ultimately becomes a national security issue. Child care benefits, family leave and subsidized, part-time work schedules for parents could be the governments strategy to encourage a new baby boom.

We may be well into the digital age, but you might not find too many iPads in the nurseries of the future. Increased awareness of the pitfalls of screen time could change our approach to parenting via device. The original scions of social media themselves now admit to limiting their own childrens time online, observes Saxbe. In fact, in some of the more expensive private schools in Los Angeles, you have to sign a no screen time pledge.

The keywords there might be expensive and private. A movement away from childhood spent online could leave behind children from poorer families as technology becomes cheaper and the cost of human labor rises. It will likely soon be less expensive to instruct classrooms of kids via lessons on tablets than by engaging a human teacher.

You might end up with a two-class system, Saxbe warns. You have more kids having a digital childhood thats a little less regulated, especially in neighborhoods where its not safe to play outside. Wealthier families are going to be able to afford more hands-on child care and more hands-on educational activities, instead of leaving kids alone with their technology.

However, technology can still benefit the family in the coming decades. In fact, Saxbe believes this is a largely untapped opportunity with great potential. Silicon Valley technologists primarily childless young men still havent tackled devices like the breast pump or baby monitor, which could both use a redesign.

Has there been a real focus on innovation and investment when it comes to things that serve parents and families yet? asks Saxbe. I think theres a big market there.

Working 10-4

After dropping your child off at day care, you head to work. You likely wont be putting the keys in the ignition of your own car, though. Kyla Thomas, sociologist at the USC Dornsife Center for Economic and Social Research and director of LABarometer, a quarterly internet-based survey of approximately 1,800 L.A. county residents, says that by 2030 commuters will probably rely more on public transit and shared, autonomous vehicles to get around.

Public transportation will be faster and more convenient, and increased density in neighborhoods will mitigate sprawl. Parking will be more expensive and harder to find. By 2100, Thomas says, private car ownership will be a thing of the past.

Hopping out of your driverless commuter van, you clock in at the office for your six-hour work day. Patricia Grabarek, lecturer with USC Dornsifes Online Master of Science in Applied Psychology program, believes that the traditional 40-hour work week could get phased out by 2050.

We are in the midst of a job revolution thats on the scale of the Industrial Revolution, Grabarek says. The entire nature of work will change.

Automation promises to replace many jobs, and streamline others. Combine this with the growing emphasis on work-life balance, embodied by current millennials pushing for workplace flexibility, and we could see our work week lighten in load.

Our leaders are recognizing the problem that employees are burning out. People are working too much and they are not as productive as they could be. Bosses will start modeling better behaviors for their employees, Grabarek says. After-hours emails could soon be banned, as is already the case in France and Germany.

This doesnt mean well all be aimlessly underemployed, however. There is a fear that automation will eliminate jobs but, in the past, weve always replaced the jobs that weve lost. Innovators will come out and replace them with new jobs we cant even come up with now, she says.

No matter how advanced computers become, human curiosity remains superior. Automation will be good at analyzing data, Grabarek says, but the questions will still originate with human researchers.

It's Quitting Time

Finished with work for the week, youre off to start the weekend. One item not likely to be on the agenda? Attending a traditional religious service.

In the United States, theres a trend away from institutionalized religion and toward highly individualized spirituality, says Richard Flory, associate professor (research) of sociology and senior director of research and evaluation at the USC Dornsife Center for Religion and Civic Culture. People just arent interested in institutions anymore, and nothing seems to be stepping forward to replace that interface between the individual and society.

Churches and temples could find new life as condos, bars or community centers, with religion relegated to a decorative background.

Rather than kneeling in prayer, people might find themselves downing a psychedelic drug to reach personal spiritual enlightenment. Movements that center around hallucinogens such as ayahuasca, a psychoactive tea from the Amazon, have gained traction in recent years, Flory notes.

Of course, there might just be an app for it all. Consciousness hacking aims to use science to bypass years of devotion to a spiritual practice and give everyone the hard-won benefits of such a practice instantly. In the future, I could see having some sort of implanted device to get to this level of consciousness, Flory says.

Reading the Tea Leaves

You may also use your leisure time to crack open a good book one with a slightly different texture. As climate change threatens our traditional resources, more sustainable alternatives such as seaweed could step in as a paper substitute, predicts Mark Marino, professor (teaching) of writing and a scholar of digital literature.

By 2100, literature could be written across the heavens instead.

Roboticist poets will create autonomous micro-texts that will be able to swarm into collectives, self-organize, aggregate and adapt, says Marino. Bevies of these nano-rhy-bots will create superstructures that can write epics on the Great Wall of China, on the surface of Mars or in the bloodstream of their readers.

Better Living Through Quantum Computing

Aging in the New Age may mean more nontraditional family units. Older adults prefer to age and die at home, but what happens when you dont have a big family network to support that? It may mean people might be more invested in friend networks, or the idea of chosen family, says Saxbe. Cue The Golden Girls theme song.

Sean Curran, associate professor of gerontology and biological sciences, believes that a focus on increasing our health span, the period of life during which one is free from serious disease, rather than simply elongating our life spans, will improve the quality of our longer lives as we age.

The goal is to have a personalized approach to aging that takes into account an individuals genetics, environment and life history, explains Curran. The assisted living facility of the future will be patient-centered, with each resident having a personalized prescription to maintain optimal health.

Eli Levenson-Falk, assistant professor of physics and astronomy, predicts that quantum computing could unlock the development of those drugs.

Quantum computers solve problems much more swiftly and with higher information density than todays computers. Although the technology is still in its infancy, Levenson-Falk predicts that by 2050, practical quantum technologies will be used commercially by major drug companies for research and development.

Enormously complicated computational tasks like simulating a chemicals molecular structure are much more achievable through this technology.

The idea is that with a quantum computer you can sort of emulate nature, he explains. We might have the canonical example for this by 2050: the physical shape of a protein molecule.

Predicting this shape is nearly impossible with a classical computer, Levenson-Falk says.

Measuring it is difficult and requires you to predict the shape first. With a good quantum simulator, we can emulate the protein and just let quantum mechanics do the processing for us, then measure the result at the end.

The Quantum Age

Indeed, quantum computing might solve questions that relate to the very fabric of the universe. Or at least get us closer to the answers.

Dark energy, dark matter, quantum gravity and thequantum classical transition are the principle problems existing in physics today. Quantum technologies are the best bet to solve the last one, says Levenson-Falk. Quantum sensors will probably also be used to help detect dark matter, or at least falsify some theories. And there are some proposals for using quantum technologies to poke at quantum gravity.

We cannot, of course, predict our shared future with 100 percent accuracy, but one thing we can be sure of is that it will be filled with new challenges and opportunities to create a better tomorrow. Although advances in technology will certainly help determine our future, how equitably those advances are shared in our interconnected world will also play a dominant role in shaping it.

This is a tale of two societies: You could either see things get better and more supportive for families, or you might see two-class stratification, Saxbe warns.

As the future unspools, we are given both the invaluable gift and the tremendous responsibility of deciding how we want it to look. Whether our world in 2100 takes on the dystopian qualities of Blade Runner or embodies the utopian, egalitarian ideals of Star Trek remains in the terrestrial hands of those already building that future.

Original post:
A Brighter Tomorrow > News > USC Dornsife - USC Dornsife College of Letters, Arts and Sciences

Read More...

ViraxClear Receives ISP Approval for ViraxClear Rapid Test Kit Distribution to Chile With Signed LOI for up to 3 million Test Kits – GlobeNewswire

July 7th, 2020 4:49 pm

VANCOUVER, British Columbia, July 07, 2020 (GLOBE NEWSWIRE) -- Global Care Capital Inc. (CSE: HLTH, FRANKFURT: L6V1) (the Company or Global Care) a global investment company which engages in early stage investment opportunities in private and public companies, is pleased to announce that its portfolio company, ViraxClear, through its joint venture, Shanghai Biotechnology Devices Ltd. (SBD) has received approval on July 3rd, 2020 from El Instituto de Salud Pblica de Chile (ISP) for the distribution of COVID-19 Rapid Antibody Test Kits (Test Kits) supplied by its previously disclosed manufacturing partners, Innovita Biological Technology Co., Ltd and Vazyme Biotech Co., Ltd (Innovita, Vazyme), for the Chilean market. ViraxClear has signed a non-binding LOI with Biosonda Biotecnologia (Biosonda) for the distribution of up to 3 million Test Kits for the Chilean market, a contract valued at up to $17.25 million in gross revenue.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f21c6f66-8b2f-4b6c-a13d-fd8e9822d37b

Distribution Contract for Test Kits in Chile

ViraxClear has received initial orders for trials and market testing of their Test Kits for the Chilean market and manufacturing is expected to commence over the next 60 days. The LOI provides for a 60-day exclusivity period during which ViraxClear and Biosonda intend to sign a definitive agreement with a total contract value of up to $17.25 million.

Biosonda is a biotechnology company founded in Chile in 1992 by leading scientists. It is currently one of the main distribution companies of products for scientific research and clinical diagnosis in Chile, with a recognizable corporate image in the national market. Biosonda works with some of the top global brands in the clinical and diagnostic industries and handle everything from marketing, import, logistics, research and development and sales.

The Biosonda commercial department is made up of a sales force, with a high degree of specialization and extensive experience in the market made up of experts in molecular biology and immunology. They offer a technical service laboratory for equipment maintenance, repair and training, a personalized after-sales service, and a commercial-logistics team that manages the tasks of quotation, import, logistics, inventory, orders and dispatch to provide an optimum service.

Alex Somjen, CEO of Global Care Capital Inc., stated, This distribution deal represents the culmination of months of negotiating by ViraxClear with top distributors in key global regions. Biosonda is in a perfect position to roll out mass testing for the region with Chile already seeing 288,000 confirmed cases of COVID-19 and the population requiring Antibody Testing once the curve has flattened.

ISP Approval

The Chilean government require medical testing devices to receive ISP Approval before they can be sold in Chile. Both Innovita and Vazyme, ViraxClear suppliers, are now on the list of ISP Approved factories, allowing ViraxClear tests to be imported and sold nationally.

Established in 2006, Innovita is a Chinese high-tech enterprise specialized in R&D, manufacturing, marketing and after-sales service of In-vitro diagnostic tests. The CE and NMPA (formerly known as CFDA) approved Innovita serology tests have performed particularly well during preliminary clinical tests carried out by the COVID-19 Testing Project; a multidisciplinary team of researchers and physicians at UCSF, UC Berkeley, Chan Zuckerberg Biohub and Innovative Genetics Institute. According to their studies, Innovita tests scored a 96.3 % specificity (NPV); 83.3% Sensitivity (PPV) with an IN-HOUSE ELISA test (gold reference standard) giving 99.1 % specificity (NPV); 81.8 % Sensitivity (PPV): https://covidtestingproject.org/

Vazyme, which isa highly reputable producer of enzymes and antibodies with products covering clinical diagnosis, molecular diagnostics, high-throughput sequencing and life science research, as well as RNA sequencing, enabling customers and reagent manufacturers to get enzymes with higher resistance. Vazyme owns a dedicated 8000 m2 R&D site and have established the Biotechnology Industry Research Institute, which is comprised of a team of nearly 100 scientists.

The Test Kits are intended for the qualitative detection of IgG and IgM antibodies against 2019 Novel Coronavirus, produced by the immune system after virus infection. IgM is the earliest antibody that appears upon the first immune response, with detection indicating an early stage infection. IgG is produced later and lasts a long time in the body, indicating a prior infection. The combination of the two markers offers an insight into what stage the virus has reached.

About ViraxClear

ViraxClear focuses on commercializing novel products that address significant healthcare needs with a specifictarget on the novel coronavirus (COVID-19). The companys main focus is marketing its ViraxClear Rapid IgM-IgG Combined Antibody Test. The ViraxClear Rapid IgM-IgG Combined Antibody Test for COVID-19 is a lateral flow immunoassay used to qualitatively detect both earlyand late marker IgG/IgM antibodies.

http://www.viraxclear.com

info@viraxclear.com

About Global Care

Global Care Capital is a global investment company which specializes in providing early stage financing to private and public companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining positions in early stage investment opportunities that adequately reflect the risk profile.

Home

GLOBAL CARE CAPITAL INC.:

Company Contact:

Alex Somjen, President & CEO

asomjen@globalcarecapital.com

Neither the CSE nor its regulation services provider accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed forward-looking statements. The use of any of the words anticipate, continue, estimate, expect, may, will, would, project, should, believe and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Companys disclosure documents which can be found under the Companys profile on http://www.sedar.com

Excerpt from:
ViraxClear Receives ISP Approval for ViraxClear Rapid Test Kit Distribution to Chile With Signed LOI for up to 3 million Test Kits - GlobeNewswire

Read More...

Is Meat Grown in a Lab Really Meat? – The New York Times

July 7th, 2020 4:48 pm

What is meat?

That question is unlikely to be asked along with the usual ones Medium or well-done? Cheese or no cheese? over grills being fired up all over the United States this summer. (Unless, of course, you invite a philosopher to your barbecue.) But it is a timely one and how we answer it how we ultimately define the word meat could have a significant impact on the future of our food supply, our health and the health of the planet.

Its no secret by now that the case against meat keeps getting stronger. The social, environmental and ethical costs of industrial agriculture exacerbated by a pandemic being traced back to a live animal market, and a vulnerable meat processing industry have become too obvious and damaging to ignore. Yet Americans on average consume more that 200 pounds of animal flesh each year. And, like it or not, it is still part of how the United States sees itself cultural icons, from cowboys and ranchers to the Golden Arches, express the countrys long, tragic love affair with meat.

But just as the meaning of American identity has changed over time, so too has the food people eat to celebrate it. Fifty years ago, few barbecues included burgers made of tofu or lentils for the stray vegetarians found in so many families today.

For centuries, the definition of meat was obvious: the edible flesh of an animal. That changed in 2013, when the Dutch scientist Mark Post unveiled the first in vitro hamburger. By bathing animal stem cells with growth serum, Dr. Post and his colleagues were able to grow a hamburger in their lab. Their burger had essentially the same composition as a normal hamburger but a different origin. Although Dr. Post estimated that the first in vitro burger cost about $325,000 to create, the price has come down significantly and his team is one of several groups seeking to commercialize in vitro meat and bring it to market. (Dr. Posts first burger was grown using fetal bovine serum, a slaughterhouse byproduct; his team and others have sought out animal-free replacements.)

This prospect has triggered opposition from the agriculture industry, which in the past three years has petitioned lawmakers in some 25 states to introduce bills to prevent alternative meat products being labeled meat.

The timing of these bills is not coincidental. Lawmakers know that plant-based meat substitutes have become big business: In 2019, plant-based meat sales totaled $939 million, an 18 percent increase over the year before, while sales for all plant-based foods reached $5 billion. The real reason for the meat industrys interest in grocery labels is that it is threatened by this surge in popularity.

Missouri was the first jurisdiction where such a bill became law and it has already been subject to a first-amendment challenge, a fate that most likely awaits its counterparts in other states.

The debates now going on in many different state legislatures and courthouses all revolve around this question: What is meat? The best answer, in my view, is one that takes the arrival of in vitro flesh as occasion to reconceive and broaden our idea of meat.

A helpful distinction is drawn by Jeff Sebo, the director of the animal studies program at New York University, between a food items origin, substance and function. The traditional view of meat holds that its must originate in the body of an animal. The substance of meat is what it is physically made of: muscle tissue composed of protein, water, amino acids and the rest. Meats function is on one level something that we experience the familiar combination of taste and texture in the mouth. Nutritionally, meats function varies it can affect our health for better or worse, depending on how we prepare it or how much we consume.

A new framework that would allow us to classify lab grown meat as just meat would involve rethinking those principles. In vitro meat generally satisfies the last two requirements substance and function but not the first, origin. (I dont include plant-based products here because they do not meet any of the three conditions.)

It may seem like cheating to consciously redefine meat in order to accommodate the lab-grown version. In fact, history is full of this type of conceptual revision. Someone asking 100 years ago what a car is could be forgiven for offering a definition that mentioned an internal combustion engine or a human driver. In the age of self-driving and electric cars we recognize that these are no longer defining features of cars. Similarly, the commonly accepted definition of marriage was that of a union between a man and a woman. When same-sex marriage was legalized in the United States that version was reclassified as but one option among others, all equally legitimate.

Revised understandings of cars and marriage involve the same kind of shift. In the jargon of philosophers, we realized that we had long been mistaking one particular conception of cars or marriage for the very concept. Revising our understanding of meat to make room for in vitro meat involves a similar move. We should strip down our understanding of meat so that an element previously deemed essential in this case, being sourced in an animal carcass is no longer strictly necessary. On this updated, more minimalist understanding, all that is necessary for something to qualify as meat is that it has a meaty substance and function. Just as Model Ts and Teslas both qualify as cars, animal-sourced and lab-grown versions would then both qualify as real meat.

Two considerations support trimming the conceptual fat from our understanding of meat in this way. The first is intuitive. Imagine you are served two pieces of steak, one from a slaughterhouse the other from a lab, which have an identical taste and nutritional effect. Food is by definition what we eat, and if our experience of eating the two morsels is the same surely they warrant a common concept.

The second is linguistic. We use the word milk to classify fluids from cows, coconuts and nursing mothers, among other sources. If milk can have more than one origin, why not meat?

Ludwig Wittgenstein argued in Philosophical Investigations that the meaning of a word is its use in the language. Given that the term in vitro meat and its synonyms (lab-grown meat, cultured meat) are already widely used, it is tempting to go the full Wittgenstein and cite common usage as grounds to declare the case for in vitro meat closed. But, to be fair, a conceptual debate should not come down to a popularity contest: same-sex marriage was once unpopular, yet that hardly settled the dispute over the nature of marriage. A more cautious handling of the linguistic evidence takes it to place the burden of proof on those who would define meat to exclude the in vitro version. Our default presumption should be that it is meat, barring good arguments otherwise.

Such definitions are disingenuous, motived by financial considerations rather than a good-faith inquiry into the meaning of terms.

Our ancestors regarded animals in a host of different ways as currency, transportation, even objects of religious veneration that may now seem strange to us. In vitro meat holds out the possibility that our descendants may someday feel the same way about eating them.

Andy Lamey teaches philosophy at the University of California, San Diego and is the author of Duty and the Beast: Should we Eat Meat in the Name of Animal Rights?

Now in print: Modern Ethics in 77 Arguments, and The Stone Reader: Modern Philosophy in 133 Arguments, with essays from the series, edited by Peter Catapano and Simon Critchley, published by Liveright Books.

The Times is committed to publishing a diversity of letters to the editor. Wed like to hear what you think about this or any of our articles. Here are some tips. And heres our email: letters@nytimes.com.

Follow The New York Times Opinion section on Facebook, Twitter (@NYTopinion) and Instagram.

The Times is committed to publishing a diversity of letters to the editor. Wed like to hear what you think about this or any of our articles. Here are some tips. And heres our email: letters@nytimes.com.

Follow The New York Times Opinion section on Facebook, Twitter (@NYTopinion) and Instagram.

Follow this link:
Is Meat Grown in a Lab Really Meat? - The New York Times

Read More...

What if mammoths are brought back from extinction? – The Economist

July 7th, 2020 4:48 pm

Jul 4th 2020

Editors note: Each of these climate-change articles is fiction, but grounded in historical fact and real science. The year, concentration of carbon dioxide and average temperature rise (above pre-industrial average) are shown for each one. The scenarios do not present a unified narrative but are set in different worlds, with a range of climate sensitivities, on different emissions pathways

IN THE LATE 1980s Michael Crichton, a novelist and filmmaker, had a lucrative idea. He picked up on the work of Allan Wilson, a geneticist at the University of California, Berkeley, and let his imagination run riot. Wilson had extracted DNA from an extinct type of zebra called a quagga. The DNA in question was fragmented, and the extinction of the quagga only a century in the past, but that did not matter. Crichton speculated about recovering far older DNA than the quaggas by looking in the guts of bloodsucking insects preserved in amber that had formed millions of years ago, during the age of the dinosaurs. If the insects had been feasting on dinosaurs, he mused, they might have preserved those creatures DNA. And if you have somethings DNA you could, perhaps, recreate it. The result was Jurassic Park.

Sadly, there is no sign of any real DNA having been preserved from that far back in the past. But be a bit less ambitious in your time-travelling, and apply the three decades worth of biotechnological advances that have happened since Jurassic Park was published to the question of how you might go forward from here, and the aspiration of recreating at least some prehistoric creatures no longer seems completely fanciful. It may, moreover, be of practical importance, because one animal the de-extinctionists have in their sights is the woolly mammoth. And some people believe that reintroducing mammoths into the wild would make a change to the ecology of Earths northern reaches sufficiently large as to help curb global warming.

This, then, is the idea behind the Harvard Woolly Mammoth Revival Project, run by George Church. Unlike the long-dead dinosaurs in Jurassic Park, mammoths were present on Earth as recently as 4,000 years ago. That, and the fact that many of the parts of the world in which they lived are still pretty chilly, means quite a lot of mammoth DNA remains reasonably intact in frozen corpses recovered from the tundraenough for palaeogeneticists to have reconstructed the animals genome. And with a genome, as Crichton mused, you can aspire to produce an animal.

Mammoths are a species of elephant. This helps because two (or, according to some taxonomists, three) other species of these animals remain alive today to provide assistance to the mammoth-revivers. Though African elephants (one species, or possibly two) are closer in size to mammoths than their Asian cousins are, genetics show that the Asian variety are mammoths closest living relatives, so it is they that are the focus of Dr Churchs research.

People once fantasised about cloning a mammoth directly, from cells or cell nuclei somehow revived from a fossil specimen. Dr Churchs approach is less ambitious and more realistic. It is to engineer the crucial elements of mammothness into Asian-elephant cells and then use these modified cells to create beasts which have the characteristics of mammoths, even if they are not strictly the real thing.

The technology that may make this possible is CRISPR-Cas9 gene editing, which permits precise changes to be made at particular places in an existing genome. In the case of mammoths the task does not, at first sight, seem too hard. An Asian elephants genome is 99.96% similar to a mammoths. Unfortunately, the 0.04% of difference amounts to about 1.4m places in the genome where the genetic letters of the DNA message differ between the species. Most of these differences are, admittedly, in places where they probably do not matter. But there are 2,020 exceptions which, collectively, change the nature of 1,642 genesabout 6.5% of the total. It is these differences that make mammoths and Asian elephants distinct.

Dr Churchs team are therefore concentrating on mammothising what they perceive to be the most pertinent of these genomic locations. They are tweaking the genes of laboratory-grown Asian-elephant skin cells one at a time, focusing on changes they hope will promote mammoths famed hairiness, their propensity to store layers of fat beneath their skin, their cold-adapted haemoglobin and even the protein molecules in their cell membranes that act as channels for the passage of sodium ions, and which are also adapted to the cold. Whether they also tinker with genes for size is, for now at least, undecided.

The teams hope, once enough mammothness has been engendered into these cells, is that they can then be induced, by what is now a well-established laboratory procedure, to turn from being skin cells into stem cells. A stem cell is one that has the developmental plasticity needed to give rise to all sorts of other cells as it multiplies. In the short term, this approach will let Dr Church and his colleagues grow tissues such as blood, for further study. In the longer term, perhaps using an artificial womb, a stem cell of this sort might be grown into an embryo that can be brought to term. Not quite a true mammoth. But not a bad imitation.

That is all a huge technical challenge. But it is not completely fanciful. And success would usher in the second part of the plan: to liberate groups of newly created mammothoids into the wild, and let them multiply and change the Earth. This is the long-held dream of another group of researchers, led by Sergey Zimov, who runs the Russian Academy of Sciences Northeast Scientific Station, near Cherskii. Not only is it an attractive idea in its own rightfor who could resist the idea of mammoths once again thundering over Siberia?but it might also alter the climate for the better.

Dr Zimovs plan is a grand project of biogeoengineering. Recreated mammoths are the boldest part of his aspiration to revive the grassland-steppe ecosystem that dominated Siberia until the arrival there of human beings, about 30,000 years ago. It had more or less disappeared by about 10,000 years ago, the end of the Pleistocene epoch, to be replaced by the modern tundra, which is dominated by moss and small trees.

This shift in vegetation was, Dr Zimov and his colleagues believe, a result of the extinction or near-extinction at that time of most of the areas large herbivore species. This was almost certainly a consequence of hunting by human beings. Where once there were woolly rhinoceros, musk ox, bison, saiga, yaks, wild horses and mammoths, there now remain only reindeer and elk. The hooves of those vast herds of herbivores were, he believes, the crucial factor stopping the spread of moss at the expense of grass. And the crashing bulk and appetites of the largest speciesmammoths in particularwould have dealt with young trees before they could grow up, as is still the case for elephants in what remains of Africas savannah. The loss of the grassland, climate modelling suggests, propelled an increase in temperature.

One factor driving this change was that forest and moss are darker than grassland. Their spread has therefore increased the amount of sunlight absorbed by the area they are growing in, causing warming.

A second factor was that large animals helped maintain the soil in the perpetually frozen state known as permafrost, by churning up the winter snowfall and thus bringing the soil into contact with the freezing winter air. But without them, the snow instead forms an insulating blanket that allows the soil beneath to warm up. And when permafrost melts, the organic matter in it breaks down, releasing methane and carbon dioxideboth greenhouse gases.

The third pertinent effect is that grass sequesters carbon in the soil in its roots. In Arctic habitats it would do this better than the small, sparse trees now present, and much better than moss, a type of plant that has no roots. Carbon stored this way is thus kept out of the atmosphere where, in the form of carbon dioxide, it would contribute to global warming. When the grass disappeared, the storage capacity did, too.

All these things point to the idea that restoring the Siberian grasslands at the expense of the tundra would be a good thing to do. And Dr Zimov has indeed made a start at doing so, in an area of tundra, covering 160 square kilometres (62 square miles), near his research station. In 1988 he enclosed part of this area and has gradually populated it with reindeer, Yakutian horses, elk, bison, musk ox, yaks, Kalmykian cows and sheep. These coexist with several species of predator, including lynx, wolverines and brown bears. He calls this rewilding project Pleistocene Park, and thinks it would benefit greatly from having a few mammoths, or even mammoth substitutes, in it as well.

Pleistocene Park is an experiment, but it seems to be working. Grasses now dominate large parts of it, carbon storage in the soil is going up and the rate of nutrient turnover is increasing, too. This last point is important because a faster turnover of nutrients means more animals can be supported by a given areaa prerequisite for re-establishing large herds.

Clearly, for Dr Zimovs project to have any effect on the climate it would have to be carried out on a grand scale. The Northeast Siberian coastal tundra, to give the area of habitat in which Pleistocene Park is located its proper name, covers about 850,000 square kilometres, so the park is, at the moment, a mere pinprick. It would also take many decades, even without the complication of introducing as-yet-imaginary mammothoids into the mix.

Expansive though the tundra is, however, whether that effect will be large enough to weigh in the scales of a planet-sized problem is a matter of debate. The models suggest that the global temperature rise brought about by the shift from steppe to tundra was a bit over 0.1C. Reversing this shift would, presumably, push the temperature down by a similar amount. That, as Chris Field of Stanford University, in California, who was one of the modellers, points out, would help stabilise the climate, provided global temperature rises above preindustrial levels can be kept, by other means, below 1.5-2C, the objective agreed in Paris in 2015. But if the rise were much greater than this, he thinks the permafrost would melt anywaymammoths or no.

For more coverage of climate change, register for The Climate Issue, our fortnightly newsletter, or visit our climate-change hub

This article appeared in the The World If section of the print edition under the headline "Doing the tundra quick-steppe"

Go here to see the original:
What if mammoths are brought back from extinction? - The Economist

Read More...

Stem Cell Therapy For Kidney Failure. Learn More Now …

July 7th, 2020 4:47 pm

Kidney failure (or renal failure) is a condition in which the kidneys fail to function properly. Physiologically, renal failure is described as a decrease in blood filtration (glomerular filtration rate or GFR). Clinically, this is manifested in elevated serum creatinine. Still not well understood are many of the factors that are involved in kidney failure. Researchers are studying the effects of nutritional proteins and the concentration of cholesterol in the blood.

Acute renal failure: Some kidney problems happen quickly, such as from an accident that causes kidney damage. A great loss of blood can cause sudden kidney failure, also some drugs or poisons can cause the kidneys to stop working. Such sudden drops in kidney function are called acute renal failure.Are you living with Kidney Failure? Call us today for a FREE consultation for stem cell therapy or fill out the Case Evaluation Form to begin.ProgenCells stem cell procedures are scientifically designed and professionally followed; we have one goal in mind: substantial health improvement of people with simple logistics.

We do not suggest that patients substitute their current medical doctor or abandon current treatments. Since this is a long-term protocol, is necessary that your current medical doctor continues to follow up on your case.

Information: Our medical experts study your case, your current condition as well as your health history. After a full evaluation it is decided if you could be eligible to participate in this protocol, and receive cell therapy. A multidisciplinary medical committee studies your case and honestly considers your improvement potential.

After your case is evaluated, a ProgenCell staff member will contact you regarding your particular case and potential benefits. We also answer any question you may have about the procedure or the requirements to make it happen.

Plan: Once you have consented, we can plan ahead. Because of ProgenCells high demand, it is necessary to schedule a date for your procedure at least 2 to 3 weeks in advance. Exceptions can be made when the condition of the patient requires urgent care.

Conditioning and medical procedure: When your appointment is scheduled, we will assign you an agent that will become your personal assistant related to your medical procedure. This assistant will be able to help you with administrative tasks, logistics, planning your stay, communication with the medical staff, etc. Your personal agent will provide you the proper documentation to complete your medical records and will explain the informed consent. In short, we will coordinate all thats necessary for a practical and easy stay with ProgenCell. The complete treatment from beginning to end- will take from 3 to 6 hours, depending on the case. During your recovery time you will have access to a telephone, TV and internet.Call us today for a FREE consultation or fill out the Case Evaluation Form to begin cell therapy.

Acute renal failure (ARF) is, as its name implies, a rapidly progressive loss of renal function, generally characterized by oliguria, a decreased urine production (measured as less than 400 mL per day for adults, less than 0.5 mL/kg/hour in children, or less than 1 mL/kg/hour in infants), and water imbalance of body fluids and electrolyte disorders.

Chronic renal failure (CRF) is the condition that is caused by permanent and irreversible damage to kidney function, secondary to any cause. Worldwide, the most common causes (but not the only) of chronic kidney disease include diabetes, hypertension, and obstructive diseases of the urinary tract (such as stones, tumors, etc.). It can arise from the complication of a large number of kidney diseases such as IgA nephropathy (Berger disease), inflammatory diseases of the kidney (collectively called glomerulonephritis), chronic pyelonephritis and urinary retention, and the use of toxic drugs to the kidney (particularly contrast media and some antibiotics). Terminal renal failure is the ultimate result, which usually requires dialysis until a donor can be found for a kidney transplant.

If the disease is detected early, the speed with which the damage progresses can be slowed, delaying the onset of replacement therapies and giving the patient more time to prepare for such therapy. Currently available renal replacement therapies are hemodialysis, peritoneal dialysis, and renal transplantation.

Causes of Kidney FailureIn the United States, about 80,000 people are diagnosed with kidney failure each year. This is a serious condition. Diabetes is the most common cause of kidney failure and constitutes more than forty percent of new cases. Even when drugs and diet can control diabetes, the disease can lead to nephropathy and kidney failure. There are about sixteen million diabetics in the United States and of those, about 100,000 suffer from kidney failure due to diabetes.People with kidney failure must undergo dialysis in either of two modes or transplantation to receive a kidney from a healthy donor. Blacks, American Indians, and the descendants of Hispanic Americans have diabetes, kidney disease, and renal failure in a proportion higher than the general population. Scientists have been unable to explain this phenomenon and cannot explain fully the interplay of factors leading to diabetic nephropathy. These factors include heredity, diet, and other conditions such as hypertension.

Go here to see the original:
Stem Cell Therapy For Kidney Failure. Learn More Now ...

Read More...

Anemia in chronic kidney disease – kidneyfund.org

July 7th, 2020 4:47 pm

Are you at risk for anemia?

Take our short quiz to learn more about the symptoms of anemia.

There's more to chronic kidney disease than you think...

If your kidneys are not working properly, they may not be able to help your body make the red blood cells it needs. Anemia is a common side effect of kidney disease.

Anemia happens when there are not enough red blood cells in your body.

Red blood cells carry oxygen through your bloodstream, giving you energy and helping your muscles, bones, and organs work properly.

The oxygen that we breathe in passes through our lungs and into the red blood cells.

In anemia, there are not enough red blood cells to carry this oxygen around the body.

Anemia can make you feel weak and tired because you are not getting the energy you need.

Return to top

Anybody can develop anemia, but it is very common in people with CKD. People with CKD may start to have anemia in the early stages of CKD, and anemia usually gets worse as CKD gets worse. If your kidneys are not working as well as they should, you are more likely to get anemia.

Anemia in CKD is more common if you:

Return to top

Anemia can happen with or without symptoms. Many of the symptoms of anemia can also be caused by other problems. The only way be sure if you have anemia is to get tested. If you are experiencing symptoms, it is important that you talk to your doctor.

Feeling dizzy or having difficulty concentrating may be a sign that your brain is not getting enough oxygen.

Paleness is caused by reduced blood flow or a lower number of red blood cells.

Anemia in CKD can increase your risk of heart problems because the heart has to work harder to provide blood to your body. If you experience an unusually fast heart rate or are worried about your heart health, please speak to your doctor.

Your blood may not have enough red blood cells to deliver oxygen to your muscles. By increasing your breathing rate, your body is trying to bring more oxygen into your body.

Easy fatigue, loss of energy, and reduced physical capacity

Sensitivity to the cold may mean there is not enough oxygen being delivered in the blood to your body

Take our short quiz to learn more about the symptoms of anemia.

Return to top

There are two main causes of anemia in CKD:

All of the cells in your body live for a certain amount of time and then die. Your body is always working to make new cells to replace the ones that have died. Red blood cells live for about 115 days. Your kidneys help your body make red blood cells.

Healthy kidneys make a hormone called erythropoietin (EPO). EPO sends a signal to the body to make more red blood cells. If your kidneys are not working as well as they should, they cant make enough EPO. Without enough EPO, your body doesnt know to make enough red blood cells. This means fewer red blood cells are available for carrying oxygen through your body.

Iron is a mineral found in many foods, such as meats and leafy greens. Your body uses iron to make red blood cells. A common cause of anemia in people with CKD is iron deficiency. Iron deficiency means you do not have enough iron in your body. It can be caused by not getting enough iron in your diet or by losing blood, either through blood tests or during dialysis. If you dont take in enough iron through your diet, you can get anemia. Around half of people with CKD stages 2 to 5 have some kind of iron deficiency.

There are several kinds of anemia. Anemia caused by having too little EPO or too little iron in your body are the most common in people with CKD. Talk to your doctor to learn more.

Return to top

Talk to your doctor if you think you may have anemia. The only way to know if you have anemia is to have a blood test. When you have kidney disease, your doctor will want you to have blood tests often. These tests are used to check not only your kidney function, but also for signs of any other problems, such as the number of red blood cells and how much iron you have in your body.

The test for anemia is a simple blood test to check for the amount of hemoglobin in your blood. Hemoglobin is a part of your red blood cells. Figuring out the amount of hemoglobin you have in your blood can tell your doctor how many red blood cells you have.

Your doctor may also ask you if youve noticed any symptoms, such as changes in skin color or feeling unusually tired.

Take our short quiz to learn more about the symptoms of anemia.

Return to top

Getting your anemia treated can help you feel better. Depending on the cause of your anemia, your doctor may recommend one of the following treatments:

Doctors and researchers are working on potential new treatments for anemia. New treatments in development are tested in clinical trials. If youre interested in joining a clinical trial to try an investigational new treatment for anemia, visit ClinicalTrials.gov to learn about all available clinical trials for anemia.

If you have CKD, getting early treatment for your anemia can help slow the progress of your CKD. If you think you might have anemia, talk to your doctor about getting tested.

Return to top

Anemia and end-stage renal disease (ESRD), also known as kidney failure, often go hand in hand. Most people with kidney failure who are on dialysis have anemia. Kidney transplant patients are also at higher risk for anemia. Learn more.

Click here to download a copy of the Anemia in ESRD booklet.

Return to top

Talk with your doctor or another member of your health care team to find out more about your anemia symptoms and treatment options. Our Talk to Your Doctor Guide can help you get the conversation started.

Note: This survey is not a medical diagnosis. This guide is an awareness tool designed for you and your doctor to use together. The information you provide is anonymous and will not shared.

Get started

Question 1 of 7

How often do you feel tired and/or weak and dont know why?

Not often

Sometimes

Often

How much does that bother you?

Not at all

A little

A lot

Question 2 of 7

How often do you notice your heart beating faster than normal?

Not often

Sometimes

Often

How much does that bother you?

Not at all

A little

A lot

Question 3 of 7

How often do you have trouble breathing or catching your breath?

Not often

Sometimes

Often

How much does that bother you?

Not at all

A little

A lot

Question 4 of 7

How often do you feel dizzy?

Not often

Sometimes

Often

How much does that bother you?

Not at all

A little

A lot

Question 5 of 7

How often do you have trouble concentrating?

Not often

Sometimes

Often

How much does that bother you?

Not at all

A little

A lot

Question 6 of 7

How often do you feel cold when others do not?

Not often

Sometimes

Often

How much does that bother you?

Not at all

A little

A lot

Question 7 of 7

Does your skin look unusually pale or dull?

See the article here:
Anemia in chronic kidney disease - kidneyfund.org

Read More...

Page 493«..1020..492493494495..500510..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick